

# BMJ Open

BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available.

When an article is published we post the peer reviewers' comments and the authors' responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to.

The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript.

BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (<http://bmjopen.bmj.com>).

If you have any questions on BMJ Open's open peer review process please email [info.bmjopen@bmj.com](mailto:info.bmjopen@bmj.com)

# BMJ Open

**Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041673
Article Type:	Original research
Date Submitted by the Author:	25-Jul-2020
Complete List of Authors:	Jaspers, Nicole; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine Visseren, Frank; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine van der Graaf, Yolanda; Utrecht University, Julius Center for Health Sciences and Primary Care Smulders, Yvo; Vrije Universiteit Amsterdam, University Medical Centre, department of internal medicine Damman, Olga; Amsterdam UMC, Department of Public and Occupational Health, Amsterdam Public Health research institute Brouwers, Corline; Amsterdam UMC Location AMC, Department of Public and Occupational Health, Amsterdam Public Health research institute Rutten, Guy; UMC Utrecht, ) Julius Center for Health Sciences and Primary Care Dorresteijn, Jannick; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine
Keywords:	PREVENTIVE MEDICINE, Vascular medicine < INTERNAL MEDICINE, PUBLIC HEALTH, Cardiology < INTERNAL MEDICINE

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-  
4 expectancy: does it improve decisional conflict? Three-armed, blinded, randomised  
5  
6 controlled trial.  
7  
8  
9

10  
11  
12 Authors:

13  
14 Nicole E.M. Jaspers<sup>1</sup>, Frank L.J. Visseren<sup>1</sup>, Yolanda van der Graaf,<sup>2</sup> Yvo M. Smulders<sup>3</sup>,

15  
16 Olga C. Damman<sup>4</sup>, C. Brouwers<sup>4</sup>, Guy E.H.M. Rutten<sup>2</sup>, Jannick A.N. Dorresteijn<sup>1</sup>,

17  
18 (1) 1. Utrecht University, University Medical Center Utrecht, Department of Vascular  
19  
20  
21 Medicine

22  
23 Utrecht, Utrecht, NL

24  
25 (2) Utrecht University, Julius Center for Health Sciences and Primary Care

26  
27 Utrecht, Utrecht, NL

28  
29 (3) Vrije Universiteit Amsterdam, University Medical Centre, department of internal  
30  
31  
32 medicine, Amsterdam, Noord-Holland, NL

33  
34 (4) Amsterdam UMC, location AMC, Department of Public and Occupational Health,  
35  
36  
37 Amsterdam Public Health research institute Amsterdam, Noord-Holland, NL

38  
39  
40  
41  
42  
43  
44 **Corresponding author**

45  
46 J.A.N. Dorresteijn

47  
48 Department of Vascular Medicine, University Medical Centre Utrecht

49  
50 PO Box 85500, 3508 GA Utrecht, The Netherlands

51  
52 Phone: +31 (0)88 7555161; Fax: +31 (0)30 2523741

53  
54 Email: j.a.n.dorresteijn-2@umcutrecht.nl  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To determine whether communicating personalized statin therapy-effects leads to lower decisional conflict associated with statin use among patients with stable cardiovascular disease (CVD) compared to standard (non-personalized) effects.

**Design:** Hypothesis-blinded, three-armed randomized controlled trial

**Setting and participants:** 303 statin-users with stable CVD enrolled in a cohort

**Intervention:** Participants were randomized in a 1:1:1 ratio to standard (non-personalized) practice (control-group) or one of two intervention arms. Intervention arms received standard practice plus 1) a *personalized health profile*, 2) educational videos, and 3) a structured telephone consultation. Intervention arms received personalized estimates of prognostic changes associated with both discontinuation of current statin and intensification to the most potent statin type and dose (i.e. atorvastatin 80 mg). Intervention arms differed in how these changes were expressed: either change in 10-year absolute CVD risk (iAR-group) or CVD-free life-expectancy (iLE-group) calculated with the SMART-REACH model (<http://U-Prevent.com>).

**Outcome:** Primary outcome was patient decisional conflict score (DCS) after one-month.

The score varies from 0 (no conflict) to 100 (high conflict). Secondary outcomes were collected at one or six months: DCS, quality of life, illness perception, patient activation, patient perception of statin efficacy and shared decision-making, self-reported statin adherence, understanding of statin-therapy, post-randomization low-density lipoprotein cholesterol (LDL-c) level, and physician opinion of the intervention. Outcomes are reported as median (25<sup>th</sup> – 75<sup>th</sup> percentile).

**Results:** Change in 10-year absolute CVD-risk was -2.4(-1.2 - -3.9%) from intensification and +10.2% (+7.7 - +13.5) from discontinuation. Change in CVD-free life-expectancy was +0.5 years (+0.3 – +0.8) from intensification and -2.0 years (-1.3 - -2.8) from discontinuation.

1  
2  
3 Decisional conflict differed between the intervention arms: median control 27 (20-43), iAR-  
4  
5 group 22 (11-30; p-value versus control 0.002), and iLE-group 25 (10–31; p-value versus  
6  
7 control 0.02). No differences in secondary outcomes were observed.  
8  
9

10 **Conclusion:** In patients with clinically manifest CVD, providing personalized estimations of  
11  
12 treatment-effects lowers decisional conflict associated with statin use. The results support the  
13  
14 use of personalized predictions for supporting decision-making.  
15  
16

17 **Registration:** Netherlands Trial Registry (Identifier NTR6227)  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of the study

#### Strengths:

- In our study, patients were provided with estimations of their actual causal therapy-effects, unlike many previous studies which tested the preferences of patients using hypothetical therapy-effects.
- Performance bias was limited by hypothesis blinding.

#### Limitations:

- In the control group of this clinically stable cohort population, decisional-conflict was low and the belief in the effectivity of statin medications was high.
- The personalized effects were not used directly during a clinical consultation, but provided prior to any potential consultation with a physician.
- A number of questionnaires were created specific for this study, and were thus not externally validated.

## Introduction

Several online tools have recently become available which can calculate the personalized therapy effects for various cardiovascular disease (CVD) prevention strategies. Such calculators often express the therapy-benefit in terms absolute 10-year CVD risk reduction, and most recently, in terms of gain in healthy life-expectancy.(1)

In general, using decision tools is associated with increased knowledge and less decisional conflict, and providing patients with information regarding therapy increases patient participation in medical decision-making.(1-5) However, most investigated patient decision-aids use hypothetical or non-personal effects of CVD-prevention, and not the actual, personalized causal effects an individual can expect from CVD-prevention. However, patients often desire a far greater therapy-benefit than can be expected from preventive therapy.(6-8) One survey showed that patients desire around 42 months increase in life-expectancy from life-long statin-use(6) whereas the actual benefit is often less than half this amount.(7) Being presented with an actual predicted benefit of a therapy far smaller than the benefit desired beforehand might discourage patients from using medication. Moreover, metrics to used communicate therapy-effects illicit different opinions on the value of preventive therapy, motivation to use therapy, and possibly therapy-adherence.(9-12)

We conducted a hypothesis blinded, three-armed, randomized controlled trial (RCT) to determine whether communication strategies involving personalized therapy-effects of statin therapy, expressed as change in CVD-free life-expectancy or absolute 10-year CVD-risk reduction, lead to improved decisional certainty about the use of statins compared to standard communication strategies and compared to one another.

## Methods

### Population



1  
2  
3 The SMART-Inform study was nested within the previously described Secondary  
4 Manifestations of ARterial disease (SMART) study, an ongoing, single-center, prospective  
5 cohort of patients referred to the University Medical Center Utrecht (UMCU) in the  
6 Netherlands for CVD screening. (13) All patients invited to participate in a SMART-  
7 examination were screened, telephonically informed of the SMART-Inform sub-study, and  
8 sent further information about the sub-study by mail. Additional inclusion criteria for the  
9 SMART-Inform study were current statin used, being between 45-80 years old, having CVD  
10 (i.e. coronary artery disease, cerebrovascular disease, and peripheral artery disease and  
11 abdominal aortic aneurysm). Additional exclusion criteria for the SMART-Inform was  
12 terminal malignancy, and not returning the baseline questionnaires.  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25

### 26 **Design, randomization, and follow-up**

27  
28 The SMART-Inform study was a three-armed, hypothesis-blinded, randomized controlled  
29 trial (RCT). RCT participants were informed that study goal was to investigate if information  
30 about cholesterol-lowering medications would impact motivation for use, and that everyone  
31 would receive at least standard SMART-protocol practice. Patients were blinded to treatment  
32 arm differences and allocation. The statistical algorithm R randomly designated assignment  
33 with a 1:1:1 ratio in block-sizes of 12. An independent investigator performed randomization  
34 and allocation via an anonymous patient number. The study was registered in the Netherlands  
35 Trial Registry (Identifier NTR6227). The Medical Ethics Review Committee of the UMCU  
36 approved the study. All participants provided written informed consent. Follow-up  
37 questionnaires were sent by mail one and six months post-intervention, with telephone  
38 reminders ensuing after two weeks if the questionnaires were not returned.  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53

### 54 **Patient and public involvement**

1  
2  
3 The study design and goal was discussed at an open conference of patient-organizations held  
4  
5 in Amstelveen, the Netherlands in April 2016 to gain and incorporate input from patients at  
6  
7 an early stage.  
8  
9

### 12 **Description of standard practice**

14 All participants received cardiovascular care as usually delivered by their own referring  
15  
16 general practitioner or medical specialist. In addition, all participants received written  
17  
18 information on their baseline examinations as part of the SMART-study consisting of general  
19  
20 lifestyle advice based on which treatment targets recommended by the European Society of  
21  
22 Cardiology (14) had not yet been met. (supplement 1A).  
23  
24  
25

### 26 **Intervention arms**

27  
28 In addition to standard practice, patients in the two intervention arms additionally received 1)  
29  
30 a *personalized health profile* (supplement 1B and 1C show examples for two hypothetical,  
31  
32 fictional patients), 2) educational videos via a USB device, and 3) a structured telephone  
33  
34 consultation (supplement 2). The '*personal health profile*' outlined three treatment options:  
35  
36 continue with the type and dose of statin-therapy ('current prognosis'); discontinue statin  
37  
38 therapy ('stop statins'); and intensify to maximum statin-therapy, defined as once-daily  
39  
40 atorvastatin 80 mg ('increase statins'). Intervention arms differed only in measures used to  
41  
42 communicate the prognostic change associated with the therapy-effects: 10-year risk (iAR-  
43  
44 group) or CVD-free life-expectancy (iLE-group). The USB-device contained intervention-  
45  
46 group specific educational videos on how to read and interpret the '*personal health profile*'  
47  
48 and the effect of statin-medications on CVD. The structured telephone consultation for the  
49  
50 intervention arms ensured the information regarding personal therapy effects was well-  
51  
52 received and understood by the patients. No face-to-face contact after receiving the  
53  
54 intervention was incorporated into the study; however as the information was not designed to  
55  
56  
57  
58  
59  
60

1  
2  
3 replace a physician's advice, all patients were encouraged to visit their general practitioner  
4  
5 within two weeks after to discuss the SMART-Inform study information.  
6

### 7 **Predicted therapy-effects**

8  
9  
10 The therapy-effects of statin-medication was modelled as this is a preventive medication  
11  
12 which is often used, and which the effect can easily be modelled. The personalized  
13  
14 estimations in the '*personal health profile*' were obtained with the SMART-REACH score,  
15  
16 an internationally validated model which predicts the personalized effects of CVD-prevention  
17  
18 including statin-therapy for patients aged 45-80 years with prior CVD (<http://U-Prevent.com>).<sup>(2)</sup> The score estimates the personalized effects of preventative therapy in  
19  
20 patients aged 45-80 years with prior CVD. A 1 mmol/L reduction in LDL-c was modelled to  
21  
22 correspond to the CVD-specific hazard ratio of 0.80 (15) and the expected LDL-c -reduction  
23  
24 from baseline for each statin was derived from a previous meta-analysis.<sup>(16)</sup> Supplemental  
25  
26 figure 1 shows the distribution of the predicted therapy-effects for the trial patients.  
27  
28  
29  
30  
31  
32  
33  
34

### 35 **Primary outcome**

36  
37 The study's primary outcome was the intergroup difference in experienced decisional conflict  
38  
39 at 1 month regarding the decision to continue, discontinue, or intensify statin therapy.  
40

41  
42 Decisional conflict was measured using the Decisional Conflict Scale (DCS), a validated,  
43  
44 translated, measure of patient perception of uncertainty in choosing between options.<sup>(17, 18)</sup>  
45

46  
47 The DCS consists of 16 statements pertaining to the decision to use statins as prescribed (e.g.,  
48  
49 "I am clear about which benefits matter most to me"). Summary scores range from 0 (no  
50  
51 decisional conflict) to 100 (extremely high decisional conflict). Scores >37.5 are associated  
52  
53 with feeling unsure about implementation of the decision (i.e. statin use), and those <25 are  
54  
55 associated with following through with a decision.  
56  
57

### 58 **Patient reported secondary outcomes**

1  
2  
3 Secondary outcomes at 6 months included the DCS, and quality of life measured using the  
4 eight subscales of the RAND Medical Outcomes Study Short Form Survey (SF-36).(19)  
5

6  
7 Other patient-reported secondary outcomes were reported at both 1 and 6 months. The Brief  
8 Illness Perception Questionnaire (brief IPQ)(20) was used to measure the degree to which  
9  
10 CVD was considered threatening by patients. A Visual Analog Scale (VAS) was used to  
11  
12 measure how effective patients perceived statin therapy (supplement 3). The thirteen question  
13  
14 Patient Activation Measure (PAM-13) (21) was used to assess patient knowledge, skills, and  
15  
16 confidence for self-management of health. Patient's perception of shared decision-making  
17  
18 was measured with the Shared Decision Making Questionnaire (SDMQ-9). Self-reported  
19  
20 statin adherence was determined with the 2003 Brief Medication Questionnaire (BMQ).(22)  
21  
22 Patient understanding of statin-therapy was measured with a questionnaire developed for the  
23  
24 trial (supplement 4). The possible numeric ranges and interpretation of the secondary  
25  
26 outcomes are shown in supplement 5.  
27  
28  
29  
30  
31

### 32 33 **Physician reported secondary outcomes**

34  
35 General practitioners (GPs) received a copy of the personalized health profile received by  
36  
37 their patients. Upon enrollment of the first patient from their practice, GPs were provided a  
38  
39 short telephonic explanation of the study and asked to fill in a questionnaire (supplement 6).  
40  
41 Questionnaire results and the last known post-intervention LDL-value at 6 months were  
42  
43 secondary outcomes.  
44  
45

### 46 47 **Statistical analyses**

48  
49 An intention-to-treat-analysis was performed. A minimum sample size of 258 (86 patients per  
50  
51 arm) was calculated to detect a difference of 8.5 on the DCS (alpha 0.05; power 0.80) using a  
52  
53 two-sided student t-test.(23) Differences among the three arms were detected with ANOVA.  
54  
55 If ANOVA  $p < 0.05$ , direct consecutive comparisons between arms were determined using t-  
56  
57 testing or with the Wilcoxon-rank sum test for not normally distributed data. Assumptions of  
58  
59  
60

1  
2  
3 normal (residual) distribution and homoscedasticity were visually inspected. A Kruskal-  
4  
5 Wallis one-way analysis of variance was performed to deal with heteroscedasticity. Analyses  
6  
7 were performed using R-Statistical Software, V 1.0.14.  
8  
9

## 10 **Subgroups**

11  
12 Pre-specified subgroup analyses via a two-way ANOVA investigated whether the effect of  
13  
14 the intervention on DCS at one month differed according to the following: gender; age (<65  
15  
16 versus >65); years since first CVD event (<1 versus >1 years); educational level (low,  
17  
18 medium or high (24)); low versus high patient activation (low a PAM-13 level of 1-2 and  
19  
20 high a PAM-13 level of 3-4 based on a conversion of the 100-point PAM-13 score to a 4-  
21  
22 point scale (21, 25); health literacy categories based on the Dutch version of the Newest Vital  
23  
24 Sign (NVS)(26); and disutility defined as the minimum gain in life-expectancy desired to  
25  
26 offset the inconvenience of taking a lifelong, hypothetical, idealised daily tablet.(7)  
27  
28  
29  
30  
31  
32  
33  
34

## 35 **Results**

### 36 **Participant flow**

37  
38 Between March 2017 and August 2018, 303 participants were enrolled. Baseline  
39  
40 characteristics are shown in table 1 and the flow of participants throughout the trial in figure  
41  
42 1. The primary outcome was collected in 260 participants (86%) (control=83, iAR group=87,  
43  
44 iLE group=90). Supplemental table 1 displays characteristics for those with and without the  
45  
46 primary endpoint. At one-month, 12% (n=10) of control, 8% (n=7) of iAR, and 11% (n=9) of  
47  
48 iLE patients reported increasing their statin dose after the intervention. Respective numbers  
49  
50 for decreased statin dose were 2% (n=2) in the control arm, 1% (n=1) in the iAR arm, and 3%  
51  
52 (n=3) in the iLE arm.  
53  
54  
55  
56  
57

### 58 **DCS at one month**

1  
2  
3 There was a significant difference between the groups (ANOVA  $\chi^2$ ,  $p=0.002$ ) with a median  
4 (25<sup>th</sup>-75<sup>th</sup> percentile) DCS of 27 (20–43) for control arm, 22 (11–30) for the iAR arm, and 25  
5  
6 (10–31) for iLE arm. Subsequent Wilcoxon-rank sum tests showed the difference between  
7  
8 the control and iAR arm ( $W=2707$ ,  $p=0.002$ ) and the control and iLE arm ( $W=4219$ ,  $p=0.02$ )  
9  
10 to be significant. The difference between iAR and iLE arms was not significant ( $W=3317$ ,  
11  
12  $p=0.21$ , Figure 2)  
13  
14  
15

### 16 17 **Patient reported secondary outcomes**

18  
19 After 6 months, there was no longer a significant difference between the groups in de DCS  
20  
21 score (ANOVA  $\chi^2$ ,  $p=0.10$ ) with a median DCS of 25 (16–38) for control arm, 22 (9–29) for  
22  
23 the iAR arm, and 25 (7–29) for iLE arm. All other secondary outcomes likewise showed now  
24  
25 intergroup differences. There was no difference in how threatening patients perceived their  
26  
27 CVD (Brief-IPQ) or how effective patients perceived statin medications (VAS 8) at either 1  
28  
29 or 6 months. There was no difference in PAM, understanding of statin effects, self-reported  
30  
31 adherence (BMQ Adherence Scale), or patients' perceptions of shared-decision making  
32  
33 between arms (SDMQ9). At six months, quality of life did not differ on any RAND SF-36  
34  
35 subscale (table 2).  
36  
37  
38  
39

### 40 41 **Physician reported secondary outcomes**

42  
43 Physician reported secondary outcomes are shown in supplemental table 2. Between  
44  
45 randomization and 6 months, 119 patients had their LDL-c values determined (control  $n=51$ ,  
46  
47 iAR  $n=48$ , iLE= $39$ ), with no difference in median serum LDL-c levels found (median 1.9  
48  
49 mmol/L in all groups) between study-arms. In total, 267 physicians were approached after the  
50  
51 inclusion of their first patient of which 141 (53%) participated in the questionnaire.  
52  
53  
54 Physicians believed statins-medication to be equally worthwhile for patients in all study-  
55  
56 arms. There was no difference of opinion between how iAR and iLE formats could positively  
57  
58 influence doctor-patient communication, consultation efficiency, and therapy-adherence.  
59  
60

### Subgroup analysis

No evidence of subgroup effects was found for sex (p-values for interaction =0.32), age (p=0.90), years since first CVD-event (p=0.24), number of months gain in CVD-free life-expectancy desired prior to taking an idealized medication daily (i.e. disutility, p=0.54), and educational level (p=0.09). An interaction was found for health literacy (p = 0.02). The median (25<sup>th</sup>-75<sup>th</sup> percentile) DCS scores for all subgroups are shown in supplemental table 3, and T-testing for differences in each health literacy group is shown in supplemental figure 2. Across health literacy categories, decisional conflict was lowest in the in intervention arms than in the control arms, with the largest difference between control and intervention arms found in people with a low health literacy.

### Discussion

Providing personalized estimates of the prognostic changes associated with statin use in terms of 10-year CVD risk and CVD-free life-years (compared to a control group) resulted in lower decisional conflict associated with statin use measures after one month. After six months no differences were found. Likewise, no group differences were found in secondary outcomes, which included the degree to which people perceived their CVD to be threatening, how effective patients viewed their statin-medications, or LDL-c levels after six months. This indicates that although the actual benefit from CVD-prevention may be smaller than people initially desire, providing the estimated effects of CVD prevention still positively impacts patient's opinions on taking these medications for a short period of time.

Many tools designed for decision-support report DCS differences of 8-10 points immediately post intervention in favour of the decision-aid.(23) We measured the outcomes after one month to measure provide enough time for patients to visit their physician. The already low decisional conflict in the control arm, may explain the relatively small absolute differences in

1  
2  
3 median scores found in this study (2-5 points). The gradual loss of statistical significance,  
4  
5 seen at six months, is in line with previous studies investigating the long-term effects of  
6  
7 decision-support tools of for statin medications indicating that positive results of such  
8  
9 interventions fade over time.(27)

10  
11  
12 The use of patient communication-aids is known to make people feel better informed and to  
13  
14 help them form accurate opinions of therapy benefit-harm ratios.(23, 28) A number of studies  
15  
16 have examined the effect of providing estimations of hypothetical or generalised therapy-  
17  
18 benefit to patients with clinically manifest CVD.(10, 29-31) One study examined the effect of  
19  
20 providing primary care patients without any prior statin-exposure, with the approximated  
21  
22 personalized effect of statin medications.(11, 32) Absolute risk reduction estimates resulted  
23  
24 in a greater likelihood to redeem statin-medications compared to patients who had received  
25  
26 the predictions in terms of prolongation of life. However, there were no differences in patient  
27  
28 satisfaction and confidence in decision. Patients already using medication may respond  
29  
30 differently to personalized estimations than patients initiating a new medication. Willingness  
31  
32 to take a new therapy may be more sensitive to the perceived side-effects than to the  
33  
34 perceived benefits.(33) Similarly, worry about side-effects is a stronger determinant of  
35  
36 intentional non-adherence than belief in the effectiveness of statin-medications(34). As  
37  
38 opposed to first-time statin-users, all patients in our study had already been using statins, and  
39  
40 may therefore already know if they have experienced statin-related side-effects.  
41  
42

43  
44  
45 Similar to our study, previous literature shows that patients often overestimate the relative  
46  
47 effects of medication and desire a greater absolute therapy-benefit than clinically feasible.(6,  
48  
49 7) Although the majority of patients in our study indeed desired more benefit than clinically  
50  
51 feasible (median disutility score 61 months), statin discontinuation was minimal and there  
52  
53 was no evidence of subgroup effects based on baseline disutility. Although physicians may  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 also over-estimate the effects of preventive therapy,(6) there were no inter-groups differences  
4  
5 in how physicians perceived the necessity of statin-medications.  
6

7  
8 Strengths of this study involve providing patients with estimations of their actual causal  
9  
10 therapy-effects. As we assessed current statin users, we were able to provide information on  
11  
12 multiple treatment-options. Systematically approaching cohort patients who were due to  
13  
14 receive physical examinations during a certain time-frame minimized the risk of  
15  
16 preferentially selecting patients likely to respond to personalized predictions. Use of the  
17  
18 cohort's standard procedures also allowed for a structured and well-defined control group,  
19  
20 and via the use of structured telephonic consultations it was ensured patients had each  
21  
22 interventional format explained in a similar fashion. Furthermore, the SMART-REACH  
23  
24 algorithm was published on <http://U-Prevent.com> after the randomization of the last patient,  
25  
26 reducing the risk of cross-contamination between intervention arms. Performance bias was  
27  
28 limited by hypothesis blinding. A number of study limitations should be highlighted. First, in  
29  
30 the control group of this clinically stable cohort population, decisional-conflict was low and  
31  
32 the belief in the effectivity of statin medications was high. The effects described here may  
33  
34 thus be different in a population with very recent CVD-events, or who are statin-naïve.  
35  
36 Moreover, the personalized effects were not used directly during a clinical consultation, but  
37  
38 provided prior to any potential consultation with a physician, and the effects may be different  
39  
40 compared to a population of patients who are involved in a clinical consultation in which  
41  
42 statin therapy is discussed. Second, the loss to follow-up was 14% for the primary outcome.  
43  
44 This is however lower than other communication-trials involving follow-up  
45  
46 questionnaires.(11) and baseline characteristics of missing and non-missing individuals were  
47  
48 relatively similar. Correction for baseline health literacy, a characteristic which may have  
49  
50 differed between missing and non-missing individuals did not level-off the effects. Third, in  
51  
52 particular for questions relating to drug-adherence, self-reported measures may be subject to  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 recall and reporting biases. Fourth, a number of questionnaires were created specific for this  
4  
5 study, and were thus not externally validated.  
6

7  
8 A number of risk-prediction tools capable of estimating treatment-effects for lipid-lowering,  
9  
10 blood pressure-lowering, and anti-thrombotic medications are now readily available in  
11  
12 clinical practice for patients with and without cardiovascular disease.(1) Future (cluster)  
13  
14 RCTs of general practitioners could investigate the use of such tools in populations with or  
15  
16 without prior medication use during actual consultations.  
17

18  
19 In conclusion, in patients with clinically manifest CVD advised to use statin medications,  
20  
21 providing personalized estimations of treatment-effects, both in terms of 10-year absolute  
22  
23 risk and CVD-free life-expectancy resulted in small but significantly lower decisional  
24  
25 conflict associated with statin use. The results support the use of personalized predictions of  
26  
27 absolute therapy benefit in clinical practice.  
28  
29

### 30 31 **Acknowledgements**

32  
33 Participants of the April 2016 Amstelveen PGOSupport conference; SMART research  
34  
35 nurses; R. van Petersen (data-manager); B.G.F. Dinther (cohort manager) and the SMART  
36  
37 Study Group: A. Algra MD,PhD; D.E. Grobbee, MD,PhD; G.J. de Borst, MD,PhD,  
38  
39 Department of Vascular Surgery; L.J. Kappelle, MD,PhD, Department of Neurology; T.  
40  
41 Leiner, MD,PhD, Department of Radiology; H.M. Nathoe, MD,PhD, Department of  
42  
43 Cardiology  
44  
45  
46  
47

### 48 **Funding**

49  
50  
51 Partially funded by a Netherlands Heart Foundation grant (2016T026).  
52

### 53 **Conflict of interest**

54  
55 We have read and understood BMJ policy on declaration of interests and declare that we have  
56  
57 no competing interests.”  
58

### 59 **Transparency declaration**

60

1  
2  
3 The lead author affirms that this manuscript is an honest, accurate, and transparent account of  
4 the study being reported; that no important aspects of the study have been omitted; and that  
5 any discrepancies from the study as planned (and, if relevant, registered) have been  
6 explained.  
7  
8  
9  
10  
11  
12  
13

#### 14 **Author Contributor statement**

15  
16 NEMJ, FLJV, YdG, OCD, CB, JAND contributed to the conception, design of the work and  
17 interpretation of the data, YMS & GEHMR contributed to the interpretation. NEMJ drafted  
18 the work, FLJV, YdG, OCD, CB, JAND, YMS & GEHMR critically revised the work, all  
19 authors gave final approval and agree to be accountable for the work.  
20  
21  
22  
23  
24  
25  
26  
27

#### 28 **Data sharing statement**

29  
30 Some individual deidentified participant data (including data dictionaries) may be shared  
31 upon reasonable request pending approval by the department and institution on a case-by-  
32 case basis. Approval will be based the scientific question to be answered with the data, ability  
33 of the authors of this manuscript to co-operate on the project, and compliance with contracts  
34 acquired for the questionnaires in this study and hospital and SMART-cohort policy.  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44

#### 45 **References**

- 46 1. Jaspers NEM, Ridker PM, Dorresteyn JAN, Visseren FLJ. The prediction of therapy-benefit for  
47 individual cardiovascular disease prevention: rationale, implications, and implementation. *Curr Opin*  
48 *Lipidol*. 2018.
- 49 2. Kaasenbrood L, Bhatt DL, Dorresteyn JAN, Wilson PWF, D'Agostino RB, Massaro JM, et al.  
50 Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular  
51 Disease: The SMART-REACH Model. *Journal of the American Heart Association* 2018 7(16).
- 52 3. Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelser C, et al.  
53 Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among  
54 Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report  
55 From the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*.  
56 2017;69(12):1617-36.
- 57 4. Board JBS. Joint British Societies' consensus recommendations for the prevention of  
58 cardiovascular disease (JBS3). *Heart*. 2014;100 Suppl 2:ii1-ii67.
- 59  
60

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
5. Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments, screening, and tests: a systematic review. *JAMA Intern Med.* 2015;175(2):274-86.
6. Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der Graaf Y, et al. Variation in minimum desired cardiovascular disease-free longevity benefit from statin and antihypertensive medications: a cross-sectional study of patient and primary care physician perspectives. *BMJ Open.* 2018;8(5):e021309.
7. Fontana M, Asaria P, Moraldo M, Finegold J, Hassanally K, Manisty CH, et al. Patient-accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity benefits against medication disutility. *Circulation.* 2014;129(24):2539-46.
8. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs preventive enough? A study of patients' expectation of benefit from preventive drugs. *Clin Med (Lond).* 2002;2(6):527-33.
9. Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk communication: a systematic review. *Ann Intern Med.* 2014;161(4):270-80.
10. Jegan NRA, Kurwitz SA, Kramer LK, Heinzl-Gutenbrunner M, Adarkwah CC, Popert U, et al. The effect of a new lifetime-cardiovascular-risk display on patients' motivation to participate in shared decision-making. *BMC Fam Pract.* 2018;19(1):84.
11. Harmsen CG, Kristiansen IS, Larsen PV, Nexoe J, Stovring H, Gyrd-Hansen D, et al. Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice. *Br J Gen Pract.* 2014;64(621):e199-207.
12. Misselbrook D, Armstrong D. Patients' responses to risk information about the benefits of treating hypertension. *Br J Gen Pract.* 2001;51(465):276-9.
13. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARterial disease (SMART) study: rationale and design. *Eur J Epidemiol.* 1999;15(9):773-81.
14. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J.* 2016;37(29):2315-81.
15. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670-81.
16. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ.* 2003;326(7404):1423.
17. O'Connor A. User Manual - Decisional conflict scale 1993 [updated 2010. Available from: [http://decisionaid.ohri.ca/eval\\_dcs.html](http://decisionaid.ohri.ca/eval_dcs.html).
18. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making.* 1995;15(1):25-30.
19. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* 1992;30(6):473-83.
20. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *J Psychosom Res.* 2006;60(6):631-7.
21. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. *Health Serv Res.* 2005;40(6 Pt 1):1918-30.
22. Svarstad BL, Chewning BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. *Patient Educ Couns.* 1999;37(2):113-24.
23. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people facing health treatment or screening decisions. *Cochrane Database Syst Rev.* 2017;4:CD001431.

- 1
  - 2
  - 3
  - 4
  - 5
  - 6
  - 7
  - 8
  - 9
  - 10
  - 11
  - 12
  - 13
  - 14
  - 15
  - 16
  - 17
  - 18
  - 19
  - 20
  - 21
  - 22
  - 23
  - 24
  - 25
  - 26
  - 27
  - 28
  - 29
  - 30
  - 31
  - 32
  - 33
  - 34
  - 35
  - 36
  - 37
  - 38
  - 39
  - 40
  - 41
  - 42
  - 43
  - 44
  - 45
  - 46
  - 47
  - 48
  - 49
  - 50
  - 51
  - 52
  - 53
  - 54
  - 55
  - 56
  - 57
  - 58
  - 59
  - 60
24. Statistiek CBvd. Opleidingsniveau [Available from: [https://www.cbs.nl/nl-nl-artikelen/nieuws/2008/16/bijna-evenveel-hoogopgeleide-als-laagopgeleide-nederlanders/opleidingsniveau](https://www.cbs.nl/nl-nl/artikelen/nieuws/2008/16/bijna-evenveel-hoogopgeleide-als-laagopgeleide-nederlanders/opleidingsniveau)].
25. Hibbard JH, Greene J, Shi Y, Mittler J, Scanlon D. Taking the long view: how well do patient activation scores predict outcomes four years later? *Med Care Res Rev*. 2015;72(3):324-37.
26. Damman OC, Vonk SI, van den Haak MJ, van Hooijdonk CMJ, Timmermans DRM. The effects of infographics and several quantitative versus qualitative formats for cardiovascular disease risk, including heart age, on people's risk understanding. *Patient Educ Couns*. 2018;101(8):1410-8.
27. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. *Arch Intern Med*. 2007;167(10):1076-82.
28. Legare F, Adekpedjou R, Stacey D, Turcotte S, Kryworuchko J, Graham ID, et al. Interventions for increasing the use of shared decision making by healthcare professionals. *Cochrane Database Syst Rev*. 2018;7:CD006732.
29. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing treatments: a randomized trial. *Ann Intern Med*. 2007;146(12):848-56.
30. Adarkwah CC, Jegan N, Heinzl-Gutenbrunner M, Kuhne F, Siebert U, Popert U, et al. Time-to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference? Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. *BMC Med Inform Decis Mak*. 2016;16(1):152.
31. Krones T, Keller H, Sonnichsen A, Sadowski EM, Baum E, Wegscheider K, et al. Absolute cardiovascular disease risk and shared decision making in primary care: a randomized controlled trial. *Ann Fam Med*. 2008;6(3):218-27.
32. Stovring H, Harmsen CG, Wisloff T, Jarbol DE, Nexoe J, Nielsen JB, et al. A competing risk approach for the European Heart SCORE model based on cause-specific and all-cause mortality. *Eur J Prev Cardiol*. 2013;20(5):827-36.
33. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older persons' willingness to take medication for primary cardiovascular prevention. *Arch Intern Med*. 2011;171(10):923-8.
34. Wouters H, Van Dijk L, Geers HC, Winters NA, Van Geffen EC, Stiggelbout AM, et al. Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to Different Patients. *PLoS One*. 2016;11(1):e0146272.
35. Fransen MP, Leenaars KE, Rowlands G, Weiss BD, Maat HP, Essink-Bot ML. International application of health literacy measures: adaptation and validation of the newest vital sign in The Netherlands. *Patient Educ Couns*. 2014;97(3):403-9.

1  
2  
3 Figure Legends:  
4

5 Figure 1: Participant flow during the trial  
6

7  
8 Figure 2: DCS at 1 month and Kruskal-Wallis analysis of variance and pos-hoc Wilcoxon-  
9  
10 rank sum t-test. Boxes denote the median (25<sup>th</sup>-75<sup>th</sup> percentiles). Whiskers denote the 25<sup>th</sup>  
11  
12 percentile-1.5\*(Inter-Quartile Range) and the 75<sup>th</sup> percentile + 1.5(Inter Quartile Range).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

## Tables:

**Table 1:** Baseline characteristics

	Control-group	iAR-group	iLE-group
	n=101	n=101	n=101
Age	66(59-70)	66(58-71)	64(59-71)
Gender (male)	86%	82%	85%
More than one CVD location	11%	10%	10%
Current Smoker	17%	16%	9%
Years clinically manifest CVD	0(0-10)	0(0-10)	3(0-10)
Diabetes Mellitus	14%	27%	23%
LDL-cholesterol (mmol/L)	2.0(1.7-2.4)	2.0(1.6-2.4)	2.0(1.6-2.5)
Already on maximum statin therapy	1.3%	1.0%	1.0%
Creatinin (umol/L)	84(78-93)	83(75-96)	85(75-94)
Systolic blood pressure (mmHg)	13(121-142)	13(121-143)	129(122-142)
Number of medications per day	5(4-6)	6(4-9)	6(4-8)
Disutility score	61(9-97)	61(5-97)	61(9-97)
Adequate health literacy	83%	83%	81%

**Legend:** Data are reported as mean  $\pm$  SD, median (interquartile range) or (%). CVD locations defined as coronary artery disease, peripheral artery disease, or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy was based on the Newest Vital Sign score in the baseline questionnaire(35). Disutility is months required to offset inconvenience of daily pill-taking of an idealized medication.(7) Number of

**Table 2:** Patient Reported Secondary Outcomes

	Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)			ANOVA	
	Control-group	iAR-group	iLE-group	Test-statistic	p-value
DCS (6)	25(16-38)	22(9-29)	25(7-31)	$\chi^2=15.0$	p=0.10
Brief-IPQ (1)	36(26-42)	34(28-44)	37(30-42)	F=4.6	p=0.68
Brief-IPQ (6)	34(26-43)	35(30-41)	37(29-44)	F=1.7	p=0.19
PAM (1)	60(51-70)	58(53-68)	63(56-75)	F=1.9	p=0.20
PAM (6)	64(54-77)	63(56-77)	63(56-78)	F=0.8	p=0.48
Perceived Statin Efficacy (1)	8(7-9)	8(7-9)	8(7-9)	$\chi^2=0.15$	p=0.92
Perceived Statin Efficacy (6)	8(7-9)	8(7-9)	8(7-9)	$\chi^2=0.50$	p=0.98
Understanding of therapy-effects (1)	88(75-88)	88(75-100)	88(75-100)	$\chi^2=5.9$	p=0.07
Understanding of therapy-effects (6)	88(75-100)	88(75-100)	88(63-100)	$\chi^2=1.4$	p=0.60
BMQ Adherence Risk Scale (1)	1(0-1)	1(0-1)	1(0-1)	$\chi^2=1.4$	p=0.60
BMQ Adherence Risk Scale (6)	1(0-1)	1(0-1)	1(0-1)	$\chi^2=1.7$	p=0.41
SDMQ9 (1); Reported visiting GP (n)	44(9-69); (46)	42(18-62); (58)	58(22-76); (55)	$\chi^2=1.8$	p=0.40
SDMQ9 (6); reported visiting GP (n)	44(24-73); (60)	48(32-63); (49)	62(22-84); (47)	$\chi^2=2.6$	p=0.28
RAND-36 Quality of life (6)					
Physical functioning	80(70-85)	75(60-85)	80(65-85)	$\chi^2=4.3$	p=0.11
Role limitations due to physical health	80(70-85)	75(60-85)	80(65-85)	$\chi^2=1.13$	p=0.57
Role limitations due to emotional problems	100(100-100)	100(100-100)	100(100-100)	$\chi^2=0.45$	p=0.80
Energy/fatigue	75(65-80)	70(60-80)	73(55-80)	$\chi^2=3.2$	p=0.20
Emotional well-being	84(73-92)	84(72-92)	80(72-88)	$\chi^2=4.4$	p=0.11
Social Functioning	88(75-88)	88(63-88)	88(75-88)	$\chi^2=1.4$	p=0.49
Pain	90(78-100)	90(68-100)	100(78-100)	$\chi^2=0.14$	p=0.93
General health	70(55-75)	60(49-75)	65(50-74)	$\chi^2=0.47$	p=0.10

Legend: Data are for one (1) or six (6) months.



SMART-cohort participants approached for inclusion (n=432)

Participants included and screened for eligibility (n=384)

Patients not eligible (n=81)

- No statin (n=42)
- No CVD (n=15)
- No baseline questionnaire returned (n=14)
- Age <45 or >80 years (n=8)
- Active malignancy (n=2)

Approached patients screened for eligibility (n=384)

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

Patients randomized to control (n=101)

Patients randomized to 10-year risk (n=101)

Patients randomized to CVD-free life-years (n=101)

Did not complete primary endpoint at one month (n=18)

Did not complete primary endpoint at one month (n=14)

Withdrew prior to intervention (n=10)  
Did not complete primary endpoint at one month (n=10)

Completed primary endpoint at one month (n=83)

Completed primary endpoint at one month (n=87)

Completed primary endpoint at one month (n=90)




Figure2: DCS at 1 month and Kruskal-Wallis analysis of variance and pos-hoc Wilcoxon-rank sum t-test. Boxes denote the median (25th-75th percentiles). Whiskers denote the 25th percentile-1.5\*(Inter-Quartile Range) and the 75th percentile + 1.5(Inter Quartile Range).

125x89mm (150 x 150 DPI)

## Supplement

### Supplement 1 (A, B, and C):

The following examples are for a 55-year-old non-smoking non-diabetic Dutch male, with a history of coronary heart disease systolic blood pressure of 140 mmHg, a total cholesterol of 6.0 mmol/L, a creatinine of 93 umol/L, and LDL-cholesterol of 3.4 mmol/L. The patient currently uses atorvastatin 40 mg. *Disclaimer: These examples are for a fictionalized, hypothetical patient and not based on any actual individual.*

### Supplement 1A: Anonymous example of standard-care.

Cholesterol:

Prevention program findings

The concentration of cholesterol in your blood is elevated. An elevated cholesterol level can increase the atherosclerotic process, or the accumulation of cholesterol and other deposits in the walls of your blood vessels.

Advice from the vascular team:

You are already being treated with a cholesterol lowering medication. Yet, your cholesterol level is still elevated. We therefore recommend adjusting the dose of your cholesterol lowering medication or switching to different cholesterol lowering medication. Talk to your doctor about considering this switch.

You can find more information about cholesterol and other risk factors on the internet: [www.cholesterol.nl](http://www.cholesterol.nl), [www.hartstichting.nl](http://www.hartstichting.nl), [www.voedingscentrum.nl](http://www.voedingscentrum.nl) and [www.vaatcentrum.nl](http://www.vaatcentrum.nl).

**Supplement 1B: Example of a ‘personal health profile’ for a hypothetical patient in the individualized absolute risk arm. *Disclaimer: This is a fictionalized, hypothetical patient***

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**My Personal Health Profile**

Part of the SMART-INFORM study

In this folder you will find your personal health profile, which we have made as part of your participation in the SMART-INFORM study. Elements of your medical status were used to complete the profile.

**VIDEOS MADE FOR YOU**

In this envelope, you will find six short videos designed to give you a bit of background information about this health profile and cardiovascular disease in general. The six videos are:

1. What is cardiovascular disease?
2. What is cholesterol?
3. What does a statin do?
4. Do statins have side-effects?
5. How do I read my personal health profile
6. What now?

The videos have been loaded onto the USB-card you are receiving with this Health Profile. You can watch the videos by plugging the USB card into a computer.

**PERSONAL HEALTH PROFILE**

Mr. J. Smith 73 years old	Type of cardiovascular disease Heart
You are a non-smoker	Creatinine-level (Kidney function) 100 umol/L
Blood pressure 140 / 90 mmHg	Prescribed statin Simvastatin 40 mg
Total cholesterol 4.7 mmol/L	You do not have diabetes
You do not report having atrial fibrillation (a type of abnormal heart rhythm)	You do not report having heart-failure

In order to calculate how statin medication effects your prognosis, we used the aspects of your profile listed above. We have based these aspects on the medical records on-file at the hospital.

2

**10-YEAR RISK**

A 10-year risk estimates the chance that you will suffer a heart attack, stroke, or sudden death with the next 10 years. We have estimated your 10-year risk in three different situations from which you can choose.

**THREE SITUATIONS FROM WHICH TO CHOOSE**

You can choose from the following three situations:

1. Continue with your current statin and dose, this is your current prognosis.
2. Stop taking your statin.
3. Increase your statin effectiveness by taking the highest dose of the strongest statin (atorvastatin 80mg).

**1. CONTINUE**



If you continue on your current statin and dose, your 10-year risk will be **21 %**

**2. STOP**



If you stop taking your statin, your 10-year risk will be **29 %**

**3. INCREASE**



If you increase your statin dose, your 10-year risk will be **18 %**

3

**QUESTIONS?**

If you have any questions about the SMART-INFORM study you can contact the investigators. They can be reached on weekdays on 000 00 000 00.

**WE WILL CONTACT YOU**

Within a few weeks, a researcher will be in contact with you to answer any additional questions or provide additional explanation regarding the personal health profile.



4

## Supplement 1C: Example of a 'personal health profile' for a hypothetical patient in the individualized life-expectancy arm. *Disclaimer: This is a fictionalized, hypothetical patient*



### My Personal Health Profile

Part of the SMART-INFORM study

In this folder you will find your personal health profile, which we have made as part of your participation in the SMART-INFORM study. Elements of your medical status were used to complete the profile.











### VIDEOS MADE FOR YOU

In this envelope, you will find six short videos designed to give you a bit of background information about this health profile and cardiovascular disease in general. The six videos are:

1. What is cardiovascular disease?
2. What is cholesterol?
3. What does a statin do?
4. Do statins have side-effects?
5. How do I read my personal health profile
6. What now?

The videos have been loaded onto the USB-card you are receiving with this Health Profile. You can watch the videos by plugging the USB card into a computer.

### PERSONAL HEALTH PROFILE

 Mr. J. Smith 73 years old	 Type of cardiovascular disease Heart
 You are a non-smoker	 Creatinine-level (Kidney function) 100 umol/L
 Blood pressure 140 / 90 mmHg	 Prescribed statin Simvastatin 40 mg
 Total cholesterol 4.7 mmol/L	 You do not have diabetes
 You do not report having atrial fibrillation (a type of abnormal heart rhythm)	 You do not report having heart-failure

In order to calculate how statin medication affects your prognosis, we used the aspects of your profile listed above. We have based these aspects on the medical records on-file at the hospital.

2

### DISEASE-FREE LIFE EXPECTANCY

The disease-free life-expectancy indicates how long you can expect to live without having a heart attack, stroke, or sudden death. We have estimated your disease-free life expectancy in three different situations from which you can choose.

### THREE SITUATIONS FROM WHICH TO CHOOSE

You can choose from the following three situations:

1. Continue with your current statin and dose, this is your current prognosis.
2. Stop taking your statin.
3. Increase your statin effectiveness by taking the highest dose of the strongest statin (atorvastatin 80mg).

#### 1. CONTINUE

If you continue with your current statin and dose, your disease-free life-expectancy is **76 years**

#### 2. STOP

If you stop taking your statin, your disease-free life-expectancy will be **22 months shorter**

#### 3. INCREASE

If you increase your statin dose, your disease-free life-expectancy will be **9 months longer**

3

### QUESTIONS?

If you have any questions about the SMART-INFORM study you can contact the investigators. They can be reached on weekdays on 000 00 000 00.

### WE WILL CONTACT YOU

Within a few weeks, a researcher will be in contact with you to answer any additional questions or provide additional explanation regarding the personal health profile.



4

### Supplement 2: Telephone consultation


Short motivational telephone consultation following a structured interview asking the following questions:

- Did you receive the information?
- Have you been able to watch the videos?
- Did you understand all the information?
- Which questions did you have after studying the information?
- Did you already decide which statin treatment option you prefer?
- If yes, did you discuss this with your physician?

### Supplement 3: Visual analogue scale

#### Estimation of therapy-effects

How great do you think the beneficial effects of your cholesterol lowering statin therapy are for you? Circle one number on the scale Below. A zero "0" means you believe that this medication is NOT effective for you and a ten "10" means you believe that is medication is VERY effective for you.



**Supplement 4: Patient questionnaire to assess statin knowledge**

---

What do you know about medication?

---

Below are a number of statements with answer choices. Please circle the answer choice which you believe is correct. If you do not know the correct answer, you can mark 'I don't know'

**Where in the body can you get cardiovascular disease?**

- heart                       legs                       both                       I don't know

Possible side-effects of statins is/are

- muscle pain                       breathing problems                       neither one                       I don't know

**A high cholesterol gives a greater risk of**

- stomach bleeds                       muscle or joint pain                       stroke/heart-attack                       I don't know

**By using statins, I reduce my risk of**

- stomach bleeds                       pneumonias                       heart-attacks                       I don't know

Due to the use of statins, the cholesterol levels in my blood will

- increase                       decrease                       stay the same                       I don't know

**Through the use I statins, I reduce**

- the fatty plaques in my arteries                       my blood pressure                       both                       I don't know

**How long are people usually advised to use statins?**

- for life                       0-1 years                       1-10 years                       I don't know

**How does cholesterol get into to blood?**

- My body produces cholesterol                       I get it from my food                       Both answers are correct                       I don't know

### Supplement 5: Secondary outcomes score ranges

Scores on the IPQ range from 0 (non-threatening) to 80 (very threatening). Patient Activation Measure (PAM-13) scores range from 0 (low activation) to 100 (high activation). Perceived statin efficacy ranged from 0 (statins perceived as ineffective) to 10 (high level of statin effectiveness). The 9-item shared decision-making questionnaire ranged from 0 (poor shared decision-making) to 100 (optimal shared decision-making). BMQ Adherence Risk Scale ranged from 0 (no-self-reported non-adherence) to 4 (self-reported non-adherence). Understanding of statin-therapy ranges from 0 (no answer correct) to 100 (all answers correct). RAND Medical Outcomes Study Short Form Survey (SF-36) questionnaire ranges from 0 (low quality of life) to 100 (high quality of life).

### Supplement 6: General practitioner questionnaire

	Definitely not (1)	Probably not (2)	Uncertain (3)	Probably yes (4)	Definitely yes (5)
1. How convinced are you that a statin is worthwhile for this patient?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Do you think the patient could benefit from a greater statin dose?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Would you consider statin discontinuation in this patient if the guidelines allowed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The following three questions are only applicable if the patient was part of an intervention arm.					
4. How probable is it that you would use this information to aid in doctor-patient communication?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Do you think the consultation would be more efficient if you had this information beforehand?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Do you think this information would encourage therapy-adherence?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Legend:** Questions 1-3 were asked of every GP. Questions 4-6 were additionally asked for physicians with patients randomized to the individualized absolute risk or the individualized life-expectancy groups.



**Supplement table 1:** Baseline characteristics per missing and non-missing for primary outcome

	Non-missing	Missing
Population	n=260	n=43
Age	66 (59 - 71)	63 (60 - 69)
Gender (male)	85%	84%
One CVD location	89%	91%
More than one CVD locations	9%	9%
Current smokers	13%	19%
Years clinically manifest CVD	1 (0 - 10)	0 (0 - 10)
Diabetes Mellitus	22%	19%
LDL-c (mmol/L)	2.0 (1.6 - 2.4)	1.9 (1.6 - 2.4)
LDL-c >1.8mmol/L	67%	52%
Creatinine (umol/L)	83 (75 - 94)	85 (79 - 97)
Systolic blood pressure (mmHg)	130 (121 - 142)	132 (119 - 146)
Number of medications per day	5 (4 - 8)	6 (4 - 8)
Months required to offset disutility of daily pill-taking	61 (6 - 97)	61 (11 - 97)
High likelihood limited literacy	7%	19%
Possibility of limited literacy	9%	12%
Adequate literacy	85%	70%
Bachelor or equivalent education	39%	37%

**Legend:** Data are reported as mean  $\pm$  SD, median (interquartile range) or n (%). CVD locations defined as coronary artery disease, peripheral artery disease, or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy based on the Newest Vital Sign baseline questionnaire.<sup>(32)</sup> Disutility derived from questionnaire based on an idealized medication<sup>(22)</sup> Number of medications excludes over the counter medications, (nasal) sprays, and topical medications.

**Supplemental table 2:** Physician reported secondary outcomes


	Median (IQR)			Analysis of Variance	
	Control-group	iAR-group	iLE-group	Test-statistic	Two-sided p-value
<b>Post-interventional LDL-c</b>					
LDL-c values determined	n=55	n=43	n=43		
No LDL-c values determined	n=27	n=42	n=42		
Post-interventional LDL-c at 6 months	1.9 (1.6 - 2.3)	1.9 (1.4 - 2.3)	1.9 (1.5 - 2.4)	F=0.50	p=0.60
<b>Physician opinion of intervention</b>					
Approached	n=93	n=88	n=87		
Participated	n=51	n=48	n=42		
Convinced that a statin is worthwhile for the patient	5 (4-5)	5 (5-5)	5 (5-5)	$\chi^2=1.4$	p=0.50
Believes patient could use a higher dose	3 (2-4)	3 (2-4)	3 (2-4)	$\chi^2=0.4$	p=0.11
Would consider statin discontinuation if guidelines allowed	2 (1-3)	2 (1-4)	2 (1-4)	$\chi^2=0.3$	p=0.84
How probable to use information†	N/A	4 (4-5)	4 (3-5)	w=978	p=0.84
Believes that consultation would be more efficient†	N/A	4 (3-5)	4 (3-5)	w=114	p=0.4
Believes that information would encourage therapy adherence†	N/A	4 (3-5)	4 (3-4)	w=1083	p=0.50

**Legend:** Data are reported as median (interquartile range) or n (%). †Only applicable for the intervention groups LDL-c=low-density lipoprotein cholesterol. Precise questions and answer choices are shown in supplement 6 "General Practitioner Questionnaire."


**Supplemental table 3: Median DCS score per subgroup strata**

	Control –group		iAR –group		iLE –group	
<b>Gender</b> (F=7.02, p-value for interaction=0.32)						
Men	29.7 (19.5 - 42.2)	n=71	23.4 (11.7 - 29.7)	n=72	25.0 (10.9 - 32.8)	n=77
Women	25.8 (21.0 - 47.7)	n=12	14.1 (10.2 - 25)	n=15	26.6 (9.4– 29.7)	n=13
<b>Age</b> (F=0.17, p-value for interaction=0.90)						
>65	19.0 (20.3 - 42.2)	n=45	18.8 (9.0 - 28.6)	n=44	25.0 (8.6 - 31.3)	n=42
≤65	30.0 (19.5 - 42.6)	n=38	23.5 (13.3 - 30.7)	n=43	25.0 (12.9 - 31.6)	n=48
<b>Patient activation</b> (F=1.4, p-value for interaction=0.40)						
Low	26.7 (14.8 - 39.1)	n=21	21.9 (3.1 - 25.0)	n=13	26.6 (24.2 - 49.2)	n=15
High	26.7 (25.2 - 42.2)	n=43	23.4 (12.5 - 30.7)	n=43	22.4 (4.7 - 29.7)	n=49
<b>Years since first CVD-event</b> (F=1.4, p-value for interaction=0.24)						
>1 year	29.7 (20.3 - 45.3)	n=33	23.4 (4.7 - 29.7)	n=43	25.0 (14.9 - 33.2)	n=52
≤1 year	26.7 (19.9 - 39.8)	n=50	21.0 (14.1 - 30.0)	n=44	23.5 (5.5 - 33.2)	n=38
<b>Educational level</b> (F=2.8, p-value for interaction=0.09)						
Low	28.1 (25.0 - 37.5)	n=14	6.3 (3.1 - 18.8)	n=17	14.1 (1.6 - 25.0)	n=15
Middle	29.7 (13.3 - 46.1)	n=35	25.0 (16.4 - 30.7)	n=40	25.0 (22.3 - 30.5)	n=38
High	26.6 (20.7 - 41.0)	n=34	21.9 (17.2 - 30.9)	n=30	25.0 (7.8 - 34.4)	n=37
<b>Health literacy*</b> (F=4.0, p-value for interaction=0.02)						
High likelihood limited literacy	50.0 (29.7 - 53.1)	n=5	7.8 (3.1 - 13.7)	n=6	28.1 (25.0 - 31.3)	n=6
Possibility limited literacy	31.2 (25.0 - 41.4)	n=7	29.7 (18.7 - 30.5)	n=7	25.0 (0.0 - 42.1)	n=9
Adequate literacy	26.6 (18.8 - 41.8)	n=70	22.7 (12.9 - 29.7)	n=74	23.4 (8.6 - 29.7)	n=75
<b>Disutility</b> (F=0.6, p-value for interaction=0.54)						
Low (<9 months)	26.6 (14.1 - 45.3)	n=23	18.8 (3.1 - 25.0)	n=25	22.7 (9.0 - 25.4)	n=24
Middle (9-97 months)	32.0 (23.4 - 44.5)	n=18	23.4 (20.7 - 28.5)	n=14	27.3 (14.8 - 41.8)	n=26
High (>97 months)	32.0 (25.0 - 43.0)	n=24	17.2 (3.1 - 29.7)	n=31	23.4 (0.39 - 35.0)	n=22

**Legend:** Data are reported as median (25<sup>th</sup> – 75<sup>th</sup> percentile). \*Further analyses for health-literacy are shown in supplemental figure 2. Patient activation level based on summary scores of the Patient Activation Measure.(16) Health literacy based on the Newest Vital Sign.(32) Due to limitations free for academic use licenses, patient activation (PAM) was only used for the last 213 participants in the study.



**Supplemental Figure 1:** Therapy-benefit from statin intensification to atorvastatin 80mg for a) iAR arm and b) iLE arm. Loss of benefit from statin discontinuation in c) iAR arm and d) iLE arm. In the iAR group, the median baseline 10-year absolute CVD risk was 37.6% (28.1-49.0). The estimated absolute 10-year risk change was -2.4% (-1.2 to -3.9) after intensification and 10.2% (7.7- 13.5) after discontinuation. In the iLE group, the median CVD-free life-expectancy was 75.4 years (73.0-82.7). The median change in CVD-free life-years was 0.5 years (0.3 – 0.8) after intensification and -2.0 years (- 1.3 - - 2.8) after discontinuation.



**Supplemental figure 2:** Subgroup analysis. Box-and-whisker plot depict the decisional conflict score at one month stratified by baseline health literacy. The colored boxes denote the median (25th – 75th percentiles). Whiskers denote the 25th percentile-1.5\*(Inter-Quartile Range) and the 75th percentile + 1.5(Inter Quartile Range) in whiskers.

**Items to include when reporting a randomized trial in a journal or conference abstract**

<b>Item</b>	<b>Description</b>	<b>Reported on line number</b>
Title	Identification of the study as randomized	Page 1, line 6
Authors *	Contact details for the corresponding author	Page 1 line 38
Trial design	Description of the trial design (e.g. parallel, cluster, non-inferiority)	Page 6, line 27
<b>Methods</b>		
Participants	Eligibility criteria for participants and the settings where the data were collected	Page 5, line 60
Interventions	Interventions intended for each group	Page 7, line 13 and 26
Objective	Specific objective or hypothesis	Page 5, line 46
Outcome	Clearly defined primary outcome for this report	Page 8, line 36
Randomization	How participants were allocated to interventions	Page 6, line 38
Blinding (masking)	Whether or not participants, care givers, and those assessing the outcomes were blinded to group assignment	Page 6, line 29
<b>Results</b>		
Numbers randomized	Number of participants randomized to each group	Page 10, line 39 & fig. 1
Recruitment	Trial status	Page 10, line 39
Numbers analysed	Number of participants analysed in each group	Fig 1
Outcome	For the primary outcome, a result for each group and the estimated effect size and its precision	Page 11, line 3 & Fig 2
Harms	Important adverse events or side effects	None
Conclusions	General interpretation of the results	Page 15, line 19
Trial registration	Registration number and name of trial register	Page 3, line 17
Funding	Source of funding	Page 15, line 51

*\*this item is specific to conference abstracts*

# BMJ Open

**Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial.**

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041673.R1
Article Type:	Original research
Date Submitted by the Author:	01-Apr-2021
Complete List of Authors:	Jaspers, Nicole; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine Visseren, Frank; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine van der Graaf, Yolanda; Utrecht University, Julius Center for Health Sciences and Primary Care Smulders, Yvo; Vrije Universiteit Amsterdam, University Medical Centre, department of internal medicine Damman, Olga; Amsterdam UMC, Department of Public and Occupational Health, Amsterdam Public Health research institute Brouwers, Corline; Amsterdam UMC Location AMC, Department of Public and Occupational Health, Amsterdam Public Health research institute Rutten, Guy; UMC Utrecht, ) Julius Center for Health Sciences and Primary Care Dorresteijn, Jannick; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Patient-centred medicine, General practice / Family practice, Communication
Keywords:	Vascular medicine < INTERNAL MEDICINE, PUBLIC HEALTH, Cardiology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, Lipid disorders < DIABETES & ENDOCRINOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.



1  
2  
3 Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-  
4 expectancy: does it improve decisional conflict? Three-armed, blinded, randomised  
5  
6 controlled trial.  
7  
8  
9

10  
11  
12 Authors:

13  
14 Nicole E.M. Jaspers<sup>1</sup>, Frank L.J. Visseren,<sup>1</sup> Yolanda van der Graaf,<sup>2</sup> Yvo M. Smulders<sup>3</sup>, Olga

15  
16 C. Damman<sup>4</sup>, C. Brouwers<sup>4</sup>, Guy E.H.M. Rutten<sup>2</sup>, Jannick A.N. Dorresteijn<sup>1</sup>

17  
18 (1) 1. Utrecht University, University Medical Center Utrecht, Department of Vascular  
19  
20  
21 Medicine

22  
23 Utrecht, Utrecht, NL

24  
25 (2) Utrecht University, Julius Center for Health Sciences and Primary Care

26  
27 Utrecht, Utrecht, NL

28  
29 (3) Vrije Universiteit Amsterdam, University Medical Centre, department of internal  
30  
31  
32 medicine, Amsterdam, Noord-Holland, NL

33  
34 (4) Amsterdam UMC, location AMC, Department of Public and Occupational Health,  
35  
36  
37 Amsterdam Public Health research institute Amsterdam, Noord-Holland, NL

38  
39  
40  
41  
42  
43  
44 **Corresponding author**

45  
46 J.A.N. Dorresteijn

47  
48 Department of Vascular Medicine, University Medical Centre Utrecht

49  
50 PO Box 85500, 3508 GA Utrecht, The Netherlands

51  
52 Phone: +31 (0)88 7555161; Fax: +31 (0)30 2523741

53  
54 Email: j.a.n.dorresteijn-2@umcutrecht.nl  
55  
56  
57  
58  
59  
60

## Abstract

**Objective:** To determine whether communicating personalized statin therapy-effects obtained by prognostic algorithm leads to lower decisional conflict associated with statin use among patients with stable cardiovascular disease (CVD) compared to standard (non-personalized) effects.

**Design:** Hypothesis-blinded, three-armed randomized controlled trial

**Setting and participants:** 303 statin-users with stable CVD enrolled in a cohort

**Intervention:** Participants were randomized in a 1:1:1 ratio to standard (non-personalized) practice (control-group) or one of two intervention arms. Intervention arms received standard practice plus 1) a *personalized health profile*, 2) educational videos, and 3) a structured telephone consultation. Intervention arms received personalized estimates of prognostic changes associated with both discontinuation of current statin and intensification to the most potent statin type and dose (i.e. atorvastatin 80 mg). Intervention arms differed in how these changes were expressed: either change in 10-year absolute CVD risk (iAR-group) or CVD-free life-expectancy (iLE-group) calculated with the SMART-REACH model (<http://U-Prevent.com>).

**Outcome:** Primary outcome was patient decisional conflict score (DCS) after one-month. The score varies from 0 (no conflict) to 100 (high conflict). Secondary outcomes were collected at one or six months: DCS, quality of life, illness perception, patient activation, patient perception of statin efficacy and shared decision-making, self-reported statin adherence, understanding of statin-therapy, post-randomization low-density lipoprotein cholesterol (LDL-c) level, and physician opinion of the intervention. Outcomes are reported as median (25<sup>th</sup> – 75<sup>th</sup> percentile).

1  
2  
3 **Results:** Decisional conflict differed between the intervention arms: median control 27 (20-  
4 43), iAR-group 22 (11-30; p-value versus control 0.002), and iLE-group 25 (10–31; p-value  
5 versus control 0.02). No differences in secondary outcomes were observed.  
6  
7  
8

9  
10 **Conclusion:** In patients with clinically manifest CVD, providing personalized estimations of  
11 treatment-effects resulted in a small but significantly lower decisional conflict after one  
12 month. The results support the use of personalized predictions for supporting decision-  
13 making.  
14  
15  
16  
17  
18

19 **Registration:** Netherlands Trial Registry (Identifier NTR6227/NL6080)  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of the study

- Patients were provided with estimations of their personalized causal therapy-effects, unlike many previous studies which used hypothetical therapy-effects.
- Performance bias was limited by hypothesis blinding.
- The decisional-conflict was low and the belief in the effectivity of statin medications was high in the control group, possibly underestimating the effect compared to the general population.
- The personalized effects were not used directly during a clinical consultation, but provided prior to any potential consultation with a physician.
- Some questionnaires were created for this study and were not externally validated.

For peer review only

## Introduction

Several online tools have recently become available which can calculate the personalized therapy effects for various cardiovascular disease (CVD) prevention strategies. Such calculators often express the therapy-benefit in terms absolute 10-year CVD risk reduction, and most recently, in terms of gain in healthy life-expectancy.(1)

The use of decision tools is associated with increased knowledge and less decisional conflict, and providing patients with information regarding therapy increases patient participation in medical decision-making.(1-5) In general, decision aids do not provide personalized benefits and harms. (6) Most investigated patient decision-aids use hypothetical or non-personal, population-based effects of CVD-prevention, and not the actual, personalized causal effects an individual can expect from CVD-prevention. However, patients often desire a far greater therapy-benefit than can be expected from preventive therapy.(7-9) One survey showed that patients desire increase in life-expectancy of around 42 months from life-long statin-use(7) whereas the actual benefit is often less than half this amount.(8) Being presented with an actual predicted benefit of a therapy far smaller than the benefit desired beforehand might discourage patients from using medication. Moreover, metrics to used communicate therapy-effects elicit different opinions on the value of preventive therapy, motivation to use therapy, and possibly therapy-adherence.(10-13)

We conducted a hypothesis blinded, three-armed, randomized controlled trial (RCT) to determine whether communication strategies involving personalized therapy-effects of statin therapy obtained by algorithm, expressed as change in CVD-free life-expectancy or absolute 10-year CVD-risk reduction, lead to improved decisional certainty about the use of statins compared to standard communication strategies and compared to one another.

## Methods

### Population

The SMART-Inform study was nested within the previously described Secondary Manifestations of ARterial disease (SMART) study, an ongoing, single-center, prospective cohort of patients referred to the University Medical Center Utrecht in the Netherlands for CVD screening. (14) All patients invited to participate in a SMART-examination were telephonically informed of the SMART-Inform sub-study and sent further information about the sub-study by mail. Additional inclusion criteria for the SMART-Inform study were current statin use, being between 45-80 years old, having CVD (i.e. coronary artery disease, cerebrovascular disease, and peripheral artery disease and abdominal aortic aneurysm). Additional exclusion criteria for the SMART-Inform was terminal malignancy and not returning the baseline questionnaires.

### Design, blinding, and randomization

The SMART-Inform study was a three-armed, hypothesis-blinded, RCT. Hypothesis blinding means patients and their general practitioners were informed that everyone would receive at least standard SMART-protocol practice and that the study goal was to investigate if information about cholesterol-lowering medications would impact motivation for use, but were unaware whether the content they received was part of the active or control arms and were unaware what the primary and secondary outcomes were. Researchers and outcome assessors were not blinded. A computer generated random allocation sequence was used to assign each patient after inclusion, by order of inclusion. The investigator generating the random sequence was not involved in other aspects of the study. All other investigators had no access to the sequence.

### Ethics Statement and Registration

1  
2  
3 The Medical Ethics Review Committee of the UMCU approved the study (16-665/D). All  
4 participants provided written informed consent. The study was registered in the Netherlands  
5  
6  
7  
8 Trial Registry (Identifier NTR6227 and NL6080).  
9

### 10 11 12 **Patient and public involvement** 13

14 The study design and goal was discussed at an open conference of patient-organizations held  
15 in Amstelveen, the Netherlands in April 2016 to gain and incorporate input from patients at  
16  
17  
18 an early stage.  
19  
20  
21

### 22 23 24 **Description of standard practice** 25

26 All participants received cardiovascular care as usually delivered by their own referring  
27  
28 general practitioner or medical specialist plus written information consisting of general  
29  
30 lifestyle advice based on which treatment targets recommended by the European Society of  
31  
32 Cardiology (15). (supplement 1A).  
33  
34  
35

### 36 37 38 **Description of intervention arms** 39

40 There were three intervention arms: the control group, the 10-year risk (iAR-group) and  
41  
42 CVD-free life-expectancy (iLE-group). The control group received only standard practice.  
43  
44 Both intervention arms received standard practice plus: 1) a leaflet entitled *personalized*  
45  
46 *health profile* (supplement 1B and 1C for two fictional patients); 2) a USB device containing  
47  
48 educational videos; 3) a structured telephone consultation enforcing uptake of the information  
49  
50 (supplement 2). The *'personal health profile'* outlined the individual effect of the following  
51  
52 treatment options: 1) continue with the type and dose of statin-therapy ('current prognosis');  
53  
54 2) discontinue statin therapy ('stop statins'); 3) intensify to maximum statin-therapy, defined  
55  
56 as once-daily atorvastatin 80 mg ('increase statins'). The only difference between the  
57  
58  
59  
60

1  
2  
3 intervention arms was the measure used to communicate the prognostic change associated  
4  
5 with the therapy-effects, individual treatment effects were estimated in terms of change in 10-  
6  
7 year risk (iAR-group) or CVD-free life-expectancy (iLE-group). The USB-device contained  
8  
9 intervention-group specific educational videos on how to read and interpret the '*personal*  
10  
11 *health profile*' and the effect of statin-medications on CVD. The structured telephone  
12  
13 consultation for the intervention arms ensured the information was well-received and  
14  
15 understood by the patients. Within the SMART-study, patients are encouraged to visit a  
16  
17 treating physician to discuss the results and decide whether or not to change their statin  
18  
19 prescription. Participants are free to decide whether they want to follow-up on this advice. No  
20  
21 extra face-to-face contact after receiving the intervention was incorporated into the SMART-  
22  
23 Inform sub-study; however as the information was not designed to replace a physician's  
24  
25 advice, all patients were additionally encouraged to visit their general practitioner within two  
26  
27 weeks to discuss the SMART-Inform study information. Follow-up questionnaires were sent  
28  
29 by mail one and six months post-intervention, with telephone reminders ensuing after two  
30  
31 weeks if the questionnaires were not returned.  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Predicted therapy-effects**

41  
42 The estimations in the '*personal health profile*' were obtained with the SMART-REACH  
43  
44 score, an internationally validated model predicting the personalized effects of secondary  
45  
46 CVD-prevention for patients aged 45-80 years (<http://U-Prevent.com>).<sup>(2)</sup> The model  
47  
48 combines hazard ratio's derived from meta-analyses with a prediction algorithm  
49  
50 incorporating individual patient characteristics to derive the personalized therapy effects. A 1  
51  
52 mmol/L reduction in LDL-c was modelled to correspond to the CVD-specific hazard ratio of  
53  
54 0.80 (16) and the expected LDL-c -reduction for each statin was derived from a previous  
55  
56 meta-analysis.<sup>(17)</sup> As far as statins concerned, subgroup analyses in literature provide no  
57  
58  
59  
60



1  
2  
3 evidence for relevant differences on a relative effect scale. Therefore, personalized treatment  
4  
5 effect estimates based on the SMART-REACH score are only different on an absolute effect  
6  
7 scale. Supplemental figure 1 shows the distribution of the predicted therapy-effects for the  
8  
9 trial patients.  
10  
11  
12  
13

### 14 **Primary outcome**

15  
16  
17 The study's primary outcome was the intergroup difference in experienced decisional conflict  
18  
19 at 1 month regarding the decision to continue, discontinue, or intensify statin therapy.

20  
21 Decisional conflict was measured using the Decisional Conflict Scale (DCS), a validated,  
22  
23 translated, measure of patient perception of uncertainty in choosing between options.(18, 19)

24  
25 The DCS consists of 16 statements pertaining to the decision to use statins as prescribed (e.g.,  
26  
27 "I am clear about which benefits matter most to me"). The DCS scale measures the amount of  
28  
29 internal conflict a patient feels regarding a medical decision. Summary scores range from 0  
30  
31 (no decisional conflict) to 100 (extremely high decisional conflict). Scores >37.5 are  
32  
33 associated with feeling unsure about implementation of the decision, possibly leading to  
34  
35 discontinuation of the chosen option or fretting about the chosen option (i.e. using statins as  
36  
37 prescribed by the physician), and <25 are associated with following through with a decision.  
38  
39

40  
41 To limit loss to follow-up, patients who did not initially respond to the follow-up  
42  
43 questionnaire were approached telephonically and a reminder sent by mail if the patient could  
44  
45 not be contacted.  
46  
47  
48  
49

### 50 **Patient reported secondary outcomes**

51  
52 Secondary outcomes at 6 months included the DCS, and quality of life measured using the  
53  
54 eight subscales of the RAND Medical Outcomes Study Short Form Survey (SF-36).(20)  
55  
56

57  
58 Other patient-reported secondary outcomes were reported at both 1 and 6 months. The Brief  
59  
60

1  
2  
3 Illness Perception Questionnaire (brief IPQ)(21) was used to measure the degree to which  
4  
5 CVD was considered threatening by patients. A Visual Analog Scale (VAS) was used to  
6  
7 measure how effective patients perceived statin therapy (supplement 3). The thirteen question  
8  
9 Patient Activation Measure (PAM-13) (22) was used to assess patient knowledge, skills, and  
10  
11 confidence for self-management of health. Due to limitations on maximum population size of  
12  
13 academic use licenses, PAM-13 was only used for the last 213 study participants. Patient's  
14  
15 perception of shared decision-making was measured with the Shared Decision Making  
16  
17 Questionnaire (SDMQ-9). Self-reported statin adherence was determined with the 2003 Brief  
18  
19 Medication Questionnaire (BMQ).(23) Patient understanding of statin-therapy was measured  
20  
21 with a questionnaire developed for the trial (supplement 4). The possible numeric ranges and  
22  
23 interpretation of the secondary outcomes are shown in supplement 5.  
24  
25  
26  
27  
28  
29  
30

### 31 **Physician reported secondary outcomes**

32  
33 General practitioners (GPs) received a copy of the personalized health profile received by  
34  
35 their patients. Upon enrolment of the first patient from their practice, GPs were provided a  
36  
37 short telephonic explanation of the study and asked to fill in a questionnaire (supplement 6).  
38  
39 Questionnaire results and the last known post-intervention LDL-value at 6 months were  
40  
41 secondary outcomes. Interviewed GP's were blinded to study outcomes and treatment arm  
42  
43 differences. GPs were interviewed and questioned after being sent the intervention material  
44  
45 of their first included patient. GP's were not approached if they had subsequent patients  
46  
47 included in the study, as receiving material from multiple patients would have unblinded  
48  
49 them to treatment arm differences.  
50  
51  
52  
53  
54  
55

### 56 **Statistical analyses**

57  
58  
59  
60

1  
2  
3 We used a T-test for the sample size as the primary analysis of this trial compared the two  
4 intervention with the control group. Calculations were conducted using G\*Power version 3.1.  
5  
6 Sample size was based on an effect size (Cohen's  $d = \text{mean difference} / \text{standard deviation}$ )  
7  
8 of 0.43, a standard deviation of 0.80 to detect a mean difference of 0.34 on the 5-point scale  
9  
10 (ranging from 0-4) corresponding to 8.6 on the 100-point scale.(24, 25) A power of 80% and  
11  
12 a two-tailed alpha of 0.05 was used. A minimum of 86 patients per arm was needed.  
13  
14  
15  
16  
17

18  
19 An intention-to treat-analysis was performed. Differences among the three arms were  
20  
21 detected with ANOVA, or a Kruskal-Wallis one-way ANOVA to deal with  
22  
23 heteroscedasticity. Assumptions of normal (residual) distribution and homoscedasticity were  
24  
25 visually inspected. If ANOVA  $p < 0.05$ , pairwise comparisons between arms were determined  
26  
27 using a t-test or with the Wilcoxon-rank sum test for the difference in ranked means if  
28  
29 ANOVA assumptions were not met after transformation attempts. Analyses were performed  
30  
31 using R-Statistical Software, V 1.0.14.  
32  
33  
34  
35  
36  
37

### 38 **Subgroups**

39  
40 Pre-specified subgroup analyses were performed using an ANCOVA test to investigate  
41  
42 whether the effect of the intervention on DCS at one month differed according to the  
43  
44 following: gender; age (<65 versus >65); years since first CVD event (<1 versus >1 years);  
45  
46 educational level (low, medium or high (26)); low versus high patient activation (low a PAM-  
47  
48 13 level of 1-2 and high a PAM-13 level of 3-4 based on a conversion of the 100-point PAM-  
49  
50 13 score to a 4-point scale (22, 27); health literacy categories based on the Dutch version of  
51  
52 the Newest Vital Sign (NVS) (28); and disutility defined as the minimum gain in life-  
53  
54 expectancy desired to offset the inconvenience of taking a lifelong, hypothetical, idealised  
55  
56 daily tablet.(8) The study was not powered to detect any subgroup differences. A Bonferroni  
57  
58  
59  
60

1  
2  
3 correction corresponding to the 22 secondary outcomes was applied. The new p-value for  
4  
5 statistical significance was 0.002.  
6  
7  
8  
9

### 10 **Sensitivity analyses**

11  
12 Sensitivity analyses were performed to account for baseline characteristics possibly differing  
13  
14 in missing outcomes between trial arms by conducting an ANCOVA with gender, age,  
15  
16 smoking status, diabetes status, LDL-cholesterol (mmol/L), creatinine (umol/L), disutility  
17  
18 score, NVS health literacy, and number of medications used daily.  
19  
20  
21  
22  
23  
24  
25  
26  
27

## 28 **Results**

### 29 **Participant flow**

30  
31  
32 Between March 2017 and August 2018, 303 participants were enrolled. Baseline  
33  
34 characteristics are shown in table 1 and the flow of participants throughout the trial in figure  
35  
36 1. The primary outcome was collected in 260 participants (86%) (control=83, iAR group=87,  
37  
38 iLE group=90). Supplemental table 1 displays characteristics for those with and without the  
39  
40 primary endpoint. At one-month, 12% (n=10) of control, 8% (n=7) of iAR, and 11% (n=9) of  
41  
42 iLE patients reported increasing their statin dose after the intervention. Respective numbers  
43  
44 for decreased statin dose were 2% (n=2) in the control arm, 1% (n=1) in the iAR arm, and 3%  
45  
46 (n=3) in the iLE arm.  
47  
48  
49  
50

### 51 **DCS at one month**

52  
53 There was a significant difference between the groups (ANOVA  $\chi^2$ , p=0.002) with a median  
54  
55 (25<sup>th</sup>-75<sup>th</sup> percentile) DCS of 27 (20–43) for control arm, 22 (11–30) for the iAR arm, and 25  
56  
57 (10–31) for iLE arm. Subsequent Wilcoxon-rank sum tests showed the difference between  
58  
59  
60

1  
2  
3 the control and iAR arm (W=2707, p=0.001) and the control and iLE arm (W=4219, p=0.02)  
4 to be significant. The difference between iAR and iLE arms was not significant (W=3317,  
5  
6 p=0.21, Figure 2). All groups showed a DCS of around 25, the value associated with  
7  
8 following through with a decision.  
9  
10

### 11 12 **Patient reported secondary outcomes**

13  
14 After 6 months, there was no longer a significant difference between the groups in de DCS  
15 score (ANOVA  $\chi^2$ , p=0.10) with a median (25<sup>th</sup>-75<sup>th</sup> percentile) DCS of 25 (16–38) for  
16 control arm, 22 (9–29) for the iAR arm, and 25 (7–29) for iLE arm. All other secondary  
17 outcomes also showed no intergroup differences. There was no difference in how threatening  
18 patients perceived their CVD (Brief-IPQ) or how effective patients perceived statin  
19 medications (VAS 8) at either 1 or 6 months. There was no difference in PAM, understanding  
20 of statin effects, self-reported adherence (BMQ Adherence Scale), or patients' perceptions of  
21 shared-decision making between arms (SDMQ9). At six months, quality of life did not differ  
22 on any RAND SF-36 subscale (table 2).  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34

### 35 36 **Physician reported secondary outcomes**

37  
38 Physician reported secondary outcomes are shown in supplemental table 2. Between  
39 randomization and 6 months, 119 patients had their LDL-c values determined (control n=51,  
40 iAR n=48, iLE=39), with no difference in median serum LDL-c levels found (median 1.9  
41 mmol/L in all groups) between study-arms. In total, 267 physicians were approached after the  
42 inclusion of their first patient of which 141 (53%) participated in the questionnaire.  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60  
61  
62  
63  
64  
65  
66  
67  
68  
69  
70  
71  
72  
73  
74  
75  
76  
77  
78  
79  
80  
81  
82  
83  
84  
85  
86  
87  
88  
89  
90  
91  
92  
93  
94  
95  
96  
97  
98  
99  
100  
101  
102  
103  
104  
105  
106  
107  
108  
109  
110  
111  
112  
113  
114  
115  
116  
117  
118  
119  
120  
121  
122  
123  
124  
125  
126  
127  
128  
129  
130  
131  
132  
133  
134  
135  
136  
137  
138  
139  
140  
141  
142  
143  
144  
145  
146  
147  
148  
149  
150  
151  
152  
153  
154  
155  
156  
157  
158  
159  
160  
161  
162  
163  
164  
165  
166  
167  
168  
169  
170  
171  
172  
173  
174  
175  
176  
177  
178  
179  
180  
181  
182  
183  
184  
185  
186  
187  
188  
189  
190  
191  
192  
193  
194  
195  
196  
197  
198  
199  
200  
201  
202  
203  
204  
205  
206  
207  
208  
209  
210  
211  
212  
213  
214  
215  
216  
217  
218  
219  
220  
221  
222  
223  
224  
225  
226  
227  
228  
229  
230  
231  
232  
233  
234  
235  
236  
237  
238  
239  
240  
241  
242  
243  
244  
245  
246  
247  
248  
249  
250  
251  
252  
253  
254  
255  
256  
257  
258  
259  
260  
261  
262  
263  
264  
265  
266  
267  
268  
269  
270  
271  
272  
273  
274  
275  
276  
277  
278  
279  
280  
281  
282  
283  
284  
285  
286  
287  
288  
289  
290  
291  
292  
293  
294  
295  
296  
297  
298  
299  
300  
301  
302  
303  
304  
305  
306  
307  
308  
309  
310  
311  
312  
313  
314  
315  
316  
317  
318  
319  
320  
321  
322  
323  
324  
325  
326  
327  
328  
329  
330  
331  
332  
333  
334  
335  
336  
337  
338  
339  
340  
341  
342  
343  
344  
345  
346  
347  
348  
349  
350  
351  
352  
353  
354  
355  
356  
357  
358  
359  
360  
361  
362  
363  
364  
365  
366  
367  
368  
369  
370  
371  
372  
373  
374  
375  
376  
377  
378  
379  
380  
381  
382  
383  
384  
385  
386  
387  
388  
389  
390  
391  
392  
393  
394  
395  
396  
397  
398  
399  
400  
401  
402  
403  
404  
405  
406  
407  
408  
409  
410  
411  
412  
413  
414  
415  
416  
417  
418  
419  
420  
421  
422  
423  
424  
425  
426  
427  
428  
429  
430  
431  
432  
433  
434  
435  
436  
437  
438  
439  
440  
441  
442  
443  
444  
445  
446  
447  
448  
449  
450  
451  
452  
453  
454  
455  
456  
457  
458  
459  
460  
461  
462  
463  
464  
465  
466  
467  
468  
469  
470  
471  
472  
473  
474  
475  
476  
477  
478  
479  
480  
481  
482  
483  
484  
485  
486  
487  
488  
489  
490  
491  
492  
493  
494  
495  
496  
497  
498  
499  
500  
501  
502  
503  
504  
505  
506  
507  
508  
509  
510  
511  
512  
513  
514  
515  
516  
517  
518  
519  
520  
521  
522  
523  
524  
525  
526  
527  
528  
529  
530  
531  
532  
533  
534  
535  
536  
537  
538  
539  
540  
541  
542  
543  
544  
545  
546  
547  
548  
549  
550  
551  
552  
553  
554  
555  
556  
557  
558  
559  
560  
561  
562  
563  
564  
565  
566  
567  
568  
569  
570  
571  
572  
573  
574  
575  
576  
577  
578  
579  
580  
581  
582  
583  
584  
585  
586  
587  
588  
589  
590  
591  
592  
593  
594  
595  
596  
597  
598  
599  
600  
601  
602  
603  
604  
605  
606  
607  
608  
609  
610  
611  
612  
613  
614  
615  
616  
617  
618  
619  
620  
621  
622  
623  
624  
625  
626  
627  
628  
629  
630  
631  
632  
633  
634  
635  
636  
637  
638  
639  
640  
641  
642  
643  
644  
645  
646  
647  
648  
649  
650  
651  
652  
653  
654  
655  
656  
657  
658  
659  
660  
661  
662  
663  
664  
665  
666  
667  
668  
669  
670  
671  
672  
673  
674  
675  
676  
677  
678  
679  
680  
681  
682  
683  
684  
685  
686  
687  
688  
689  
690  
691  
692  
693  
694  
695  
696  
697  
698  
699  
700  
701  
702  
703  
704  
705  
706  
707  
708  
709  
710  
711  
712  
713  
714  
715  
716  
717  
718  
719  
720  
721  
722  
723  
724  
725  
726  
727  
728  
729  
730  
731  
732  
733  
734  
735  
736  
737  
738  
739  
740  
741  
742  
743  
744  
745  
746  
747  
748  
749  
750  
751  
752  
753  
754  
755  
756  
757  
758  
759  
760  
761  
762  
763  
764  
765  
766  
767  
768  
769  
770  
771  
772  
773  
774  
775  
776  
777  
778  
779  
780  
781  
782  
783  
784  
785  
786  
787  
788  
789  
790  
791  
792  
793  
794  
795  
796  
797  
798  
799  
800  
801  
802  
803  
804  
805  
806  
807  
808  
809  
810  
811  
812  
813  
814  
815  
816  
817  
818  
819  
820  
821  
822  
823  
824  
825  
826  
827  
828  
829  
830  
831  
832  
833  
834  
835  
836  
837  
838  
839  
840  
841  
842  
843  
844  
845  
846  
847  
848  
849  
850  
851  
852  
853  
854  
855  
856  
857  
858  
859  
860  
861  
862  
863  
864  
865  
866  
867  
868  
869  
870  
871  
872  
873  
874  
875  
876  
877  
878  
879  
880  
881  
882  
883  
884  
885  
886  
887  
888  
889  
890  
891  
892  
893  
894  
895  
896  
897  
898  
899  
900  
901  
902  
903  
904  
905  
906  
907  
908  
909  
910  
911  
912  
913  
914  
915  
916  
917  
918  
919  
920  
921  
922  
923  
924  
925  
926  
927  
928  
929  
930  
931  
932  
933  
934  
935  
936  
937  
938  
939  
940  
941  
942  
943  
944  
945  
946  
947  
948  
949  
950  
951  
952  
953  
954  
955  
956  
957  
958  
959  
960  
961  
962  
963  
964  
965  
966  
967  
968  
969  
970  
971  
972  
973  
974  
975  
976  
977  
978  
979  
980  
981  
982  
983  
984  
985  
986  
987  
988  
989  
990  
991  
992  
993  
994  
995  
996  
997  
998  
999  
1000

### 58 **Subgroup analysis**

1  
2  
3 No evidence of subgroup effects was found for sex (p-values for interaction =0.32), age  
4 (p=0.90), years since first CVD-event (p=0.24), number of months gain in CVD-free life-  
5 expectancy desired prior to taking an idealized medication daily (i.e. disutility, p=0.54), and  
6 educational level (p=0.09). An interaction was found for health literacy (p = 0.02). The  
7 median (25<sup>th</sup>-75<sup>th</sup> percentile) DCS scores for all subgroups are shown in supplemental table 3,  
8 and a t-test for differences in each health literacy group is shown in supplemental figure 2.  
9  
10 Across health literacy categories, decisional conflict was lowest in the in intervention arms  
11 than in the control arms, with the largest difference between control and intervention arms  
12 found in people with a low health literacy.  
13  
14

### 25 **Sensitivity analyses**

26 Supplemental table 4 shows the sensitivity analyses which corrected for baseline  
27 characteristics. After correction none of the outcomes were significant.  
28  
29

### 33 **Discussion**

34 Providing personalized estimates of the prognostic changes associated with statin use in  
35 terms of 10-year CVD risk and CVD-free life-years (compared to a control group) resulted in  
36 lower decisional conflict associated with statin use measures after one month. After six  
37 months no differences were found. Likewise, no group differences were found in secondary  
38 outcomes, which included the degree to which people perceived their CVD to be threatening,  
39 how effective patients viewed their statin-medications, or LDL-c levels after six months. The  
40 actual benefit from CVD-prevention is smaller than people initially report acceptable. Still,  
41 openly communicating the individual estimated of statin use on the prevention of CVD  
42 resulted in lower decisional conflict, without may people discontinuing their treatments.  
43  
44 However, the effect was small in a population with a low baseline DCS.  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Many tools designed for decision-support report DCS differences of 8-10 points immediately  
4 post intervention in favour of the decision-aid.(6) We measured the outcomes after one  
5  
6 month to provide time for patients to visit their physician. The already low decisional conflict  
7  
8 in the control arm, may explain the relatively small absolute differences in median scores  
9  
10 found in this study (2-5 points). The gradual loss of statistical significance, seen at six  
11  
12 months, is in line with previous studies investigating the long-term effects of decision-  
13  
14 support tools of for statin medications indicating that positive results of such interventions  
15  
16 fade over time. (29)

17  
18 The use of patient communication-aids is known to make people feel better informed and to  
19  
20 help them form accurate opinions of therapy benefit-harm ratios.(6, 30) A number of studies  
21  
22 have examined the effect of providing estimations of hypothetical or generalised therapy-  
23  
24 benefit to patients with clinically manifest CVD.(11, 31-33) One study examined the effect of  
25  
26 providing primary care patients without any prior statin-exposure, with the approximated  
27  
28 personalized effect of statin medications.(12) Absolute risk reduction estimates resulted in a  
29  
30 greater likelihood to redeem statin-medications compared to patients who had received the  
31  
32 predictions in terms of prolongation of life. However, there were no differences in patient  
33  
34 satisfaction and confidence in decision. Patients already using medication may respond  
35  
36 differently to personalized estimations than patients initiating a new medication. Willingness  
37  
38 to take a new therapy may be more sensitive to the perceived side-effects than to the  
39  
40 perceived benefits.(34) Similarly, worry about side-effects is a stronger determinant of  
41  
42 intentional non-adherence than belief in the effectiveness of statin-medications(35). As  
43  
44 opposed to first-time statin-users, all patients in our study had already been using statins, and  
45  
46 may therefore already know if they have experienced statin-related side-effects.  
47  
48 Similar to our study, previous literature shows that patients often overestimate the relative  
49  
50 effects of medication and desire a greater absolute therapy-benefit than clinically feasible.(7,  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 8) Although the majority of patients in our study indeed desired more benefit than clinically  
4 feasible (median disutility score 61 months), statin discontinuation was minimal and there  
5 was no evidence of subgroup effects based on baseline disutility. Although physicians may  
6  
7 was no evidence of subgroup effects based on baseline disutility. Although physicians may  
8  
9 also over-estimate the effects of preventive therapy,(7) there were no inter-groups differences  
10  
11 in how physicians perceived the necessity of statin-medications.  
12

13  
14 Strengths of this study include providing patients with estimations of their actual causal  
15  
16 therapy-effects, in contrast to pre-existing decision aids which presented participants with  
17  
18 either hypothetical or population-based therapy-effects. As we assessed current statin users,  
19  
20 we were able to provide information on multiple treatment-options. Systematically  
21  
22 approaching cohort patients who were due to receive physical examinations during a certain  
23  
24 time-frame minimized the risk of preferentially selecting patients likely to respond to  
25  
26 personalized predictions. Use of the cohort's standard procedures also allowed for a  
27  
28 structured and well-defined control group, and via the use of structured telephonic  
29  
30 consultations it was ensured patients had each interventional format explained in a similar  
31  
32 fashion. Performance bias was limited by hypothesis blinding. A number of study limitations  
33  
34 should be highlighted. First, in the control group of this clinically stable cohort population,  
35  
36 decisional-conflict was low and the belief in the effectivity of statin medications was high.  
37  
38 The effects described here may thus be different in patients who experience adverse effects  
39  
40 during statin therapy or consider starting more intensive preventive treatment options on top  
41  
42 of standard statin treatment, e.g. intensive blood pressure reduction or antithrombotic  
43  
44 treatment. Moreover, the personalized effects were not used directly during a clinical  
45  
46 consultation, but provided prior to any potential consultation with a physician, and the effects  
47  
48 may be different compared to a population of patients who are involved in a clinical  
49  
50 consultation in which statin therapy is discussed. Second, the loss to follow-up was 14% for  
51  
52 the primary outcome. This is however lower than other communication-trials involving  
53  
54  
55  
56  
57  
58  
59  
60



1  
2  
3 follow-up questionnaires(12) and baseline characteristics of missing and non-missing  
4  
5 individuals were relatively similar. Correction for baseline health literacy, a characteristic  
6  
7 which may have differed between missing and non-missing individuals did not level-off the  
8  
9 effects. Third, in particular for questions relating to drug-adherence, self-reported measures  
10  
11 may be subject to recall and reporting biases. Fourth, a number of questionnaires were  
12  
13 created specific for this study, and were thus not externally validated.  
14  
15

16  
17 A number of risk-prediction tools capable of estimating treatment-effects for lipid-lowering,  
18  
19 blood pressure-lowering, and anti-thrombotic medications are now readily available in  
20  
21 clinical practice for patients with and without CVD.(1) Statins are usually prescribed to  
22  
23 patients with CVD during hospital admission for the first CVD event. Outpatient decision-  
24  
25 making regarding statins in this population usually pertain to continuing or altering the  
26  
27 current statin dose. In the present study, we aimed to examine a setting closely resembling the  
28  
29 outpatient practice. The present study showed only a small effect in patients with a low  
30  
31 baseline DCS. Therefore future studies could focus on populations with higher baseline  
32  
33 decisional conflict such as patients experiencing adverse effects or considering more  
34  
35 intensive preventive treatment options on top of standard treatment such as intensive blood  
36  
37 pressure reduction or combination antithrombotic treatment.  
38  
39  
40  
41  
42  
43  
44

45 In conclusion, in patients with clinically manifest CVD advised to use statin medications,  
46  
47 providing personalized estimations of treatment-effects, both in terms of 10-year absolute risk  
48  
49 and CVD-free life-expectancy resulted in small but significantly lower decisional conflict  
50  
51 associated with statin use after one month follow-up. This effect of the intervention had  
52  
53 disappeared after 6 months follow-up. The results support the use of personalized predictions  
54  
55 of absolute therapy benefit in clinical practice. Future studies may focus on decisions  
56  
57 associated with higher decisional conflict such as the addition of more intensive preventive  
58  
59 treatment options on top of standard treatment.  
60

## Acknowledgements

Participants of the April 2016 Amstelveen PGOSupport conference; SMART research nurses; R. van Petersen (data-manager); B.G.F. Dinther (cohort manager) and the SMART Study Group: A. Algra MD,PhD; D.E. Grobbee, MD,PhD; G.J. de Borst, MD,PhD, Department of Vascular Surgery; L.J. Kappelle, MD,PhD, Department of Neurology; T. Leiner, MD,PhD, Department of Radiology; H.M. Nathoe, MD,PhD, Department of Cardiology

## Funding

Partially funded by a Netherlands Heart Foundation grant (2016T026). Funder was not involved in the design or assessment of the study.

## Conflict of interest

We have read and understood BMJ policy on declaration of interests and declare that we have no competing interests.”

## Transparency declaration

The lead author affirms that this manuscript is an honest, accurate, and transparent account of the study being reported; that no important aspects of the study have been omitted; and that any discrepancies from the study as planned (and, if relevant, registered) have been explained.

## Author Contributor statement

NEMJ, FLJV, YdG, OCD, CB, JAND contributed to the conception, design of the work and interpretation of the data, YMS & GEHMR contributed to the interpretation. NEMJ drafted the work and performed the analyses, FLJV, YdG, OCD, CB, JAND, YMS & GEHMR

1  
2  
3 critically revised the work, all authors gave final approval and agree to be accountable for the  
4  
5 work.  
6  
7  
8  
9

### 10 **Data sharing statement**

11  
12 Some individual deidentified participant data (including data dictionaries) may be shared  
13  
14 upon reasonable request pending approval by the department and institution on a case-by-  
15  
16 case basis. Approval will be based the scientific question to be answered with the data, ability  
17  
18 of the authors of this manuscript to co-operate on the project, and compliance with contracts  
19  
20 acquired for the questionnaires in this study and hospital and SMART-cohort policy.  
21  
22  
23  
24  
25

### 26 **References**

- 27 1. Jaspers NEM, Ridker PM, Dorresteyn JAN, Visseren FLJ. The prediction of therapy-benefit for  
28 individual cardiovascular disease prevention: rationale, implications, and implementation. *Curr Opin*  
29 *Lipidol*. 2018.
- 30 2. Kaasenbrood L, Bhatt DL, Dorresteyn JAN, Wilson PWF, D'Agostino RB, Massaro JM, et al.  
31 Estimated Life Expectancy Without Recurrent Cardiovascular Events in Patients With Vascular  
32 Disease: The SMART-REACH Model. *Journal of the American Heart Association* 2018 7(16).
- 33 3. Lloyd-Jones DM, Huffman MD, Karmali KN, Sanghavi DM, Wright JS, Pelsler C, et al.  
34 Estimating Longitudinal Risks and Benefits From Cardiovascular Preventive Therapies Among  
35 Medicare Patients: The Million Hearts Longitudinal ASCVD Risk Assessment Tool: A Special Report  
36 From the American Heart Association and American College of Cardiology. *J Am Coll Cardiol*.  
37 2017;69(12):1617-36.
- 38 4. Board JBS. Joint British Societies' consensus recommendations for the prevention of  
39 cardiovascular disease (JBS3). *Heart*. 2014;100 Suppl 2:ii1-ii67.
- 40 5. Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments,  
41 screening, and tests: a systematic review. *JAMA Intern Med*. 2015;175(2):274-86.
- 42 6. Stacey D, Legare F, Lewis K, Barry MJ, Bennett CL, Eden KB, et al. Decision aids for people  
43 facing health treatment or screening decisions. *Cochrane Database Syst Rev*. 2017;4:CD001431.
- 44 7. Jaspers NEM, Visseren FLJ, Numans ME, Smulders YM, van Loenen Martinet FA, van der  
45 Graaf Y, et al. Variation in minimum desired cardiovascular disease-free longevity benefit from statin  
46 and antihypertensive medications: a cross-sectional study of patient and primary care physician  
47 perspectives. *BMJ Open*. 2018;8(5):e021309.
- 48 8. Fontana M, Asaria P, Moraldo M, Finegold J, Hassanally K, Manisty CH, et al. Patient-  
49 accessible tool for shared decision making in cardiovascular primary prevention: balancing longevity  
50 benefits against medication disutility. *Circulation*. 2014;129(24):2539-46.
- 51 9. Trewby PN, Reddy AV, Trewby CS, Ashton VJ, Brennan G, Inglis J. Are preventive drugs  
52 preventive enough? A study of patients' expectation of benefit from preventive drugs. *Clin Med*  
53 (Lond). 2002;2(6):527-33.
- 54 10. Zipkin DA, Umscheid CA, Keating NL, Allen E, Aung K, Beyth R, et al. Evidence-based risk  
55 communication: a systematic review. *Ann Intern Med*. 2014;161(4):270-80.
- 56  
57  
58  
59  
60

11. Jegan NRA, Kurwitz SA, Kramer LK, Heinzl-Gutenbrunner M, Adarkwah CC, Popert U, et al. The effect of a new lifetime-cardiovascular-risk display on patients' motivation to participate in shared decision-making. *BMC Fam Pract.* 2018;19(1):84.
12. Harmsen CG, Kristiansen IS, Larsen PV, Nexoe J, Stovring H, Gyrd-Hansen D, et al. Communicating risk using absolute risk reduction or prolongation of life formats: cluster-randomised trial in general practice. *Br J Gen Pract.* 2014;64(621):e199-207.
13. Misselbrook D, Armstrong D. Patients' responses to risk information about the benefits of treating hypertension. *Br J Gen Pract.* 2001;51(465):276-9.
14. Simons PC, Algra A, van de Laak MF, Grobbee DE, van der Graaf Y. Second manifestations of ARterial disease (SMART) study: rationale and design. *Eur J Epidemiol.* 1999;15(9):773-81.
15. Piepoli MF, Hoes AW, Agewall S, Albus C, Brotons C, Catapano AL, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J.* 2016;37(29):2315-81.
16. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, Emberson J, Holland LE, Reith C, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet.* 2010;376(9753):1670-81.
17. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ.* 2003;326(7404):1423.
18. O'Connor A. User Manual - Decisional conflict scale 1993 [updated 2010. Available from: [http://decisionaid.ohri.ca/eval\\_dcs.html](http://decisionaid.ohri.ca/eval_dcs.html).
19. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making.* 1995;15(1):25-30.
20. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care.* 1992;30(6):473-83.
21. Broadbent E, Petrie KJ, Main J, Weinman J. The brief illness perception questionnaire. *J Psychosom Res.* 2006;60(6):631-7.
22. Hibbard JH, Mahoney ER, Stockard J, Tusler M. Development and testing of a short form of the patient activation measure. *Health Serv Res.* 2005;40(6 Pt 1):1918-30.
23. Svarstad BL, Chewing BA, Sleath BL, Claesson C. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. *Patient Educ Couns.* 1999;37(2):113-24.
24. Schwalm J, Stacey D, Pericak D, Natarajan M. Radial Artery Versus Femoral Artery Access Options in Coronary Angiogram Procedures. *Circulation: Cardiovascular Quality and Outcomes.* 2012;5:260-6.
25. O'Connor AM. Validation of a Decisional Conflict Scale. *Med Decis Making.* 1995;15(25).
26. Statistiek CBvd. Opleidingsniveau [Available from: [https://www.cbs.nl/nl-nl-artikelen/nieuws/2008/16/bijna-evenveel-hoogopgeleide-als-laagopgeleide-nederlanders/opleidingsniveau](https://www.cbs.nl/nl-nl/artikelen/nieuws/2008/16/bijna-evenveel-hoogopgeleide-als-laagopgeleide-nederlanders/opleidingsniveau).
27. Hibbard JH, Greene J, Shi Y, Mittler J, Scanlon D. Taking the long view: how well do patient activation scores predict outcomes four years later? *Med Care Res Rev.* 2015;72(3):324-37.
28. Fransen MP, Leenaars KE, Rowlands G, Weiss BD, Maat HP, Essink-Bot ML. International application of health literacy measures: adaptation and validation of the newest vital sign in The Netherlands. *Patient Educ Couns.* 2014;97(3):403-9.
29. Weymiller AJ, Montori VM, Jones LA, Gafni A, Guyatt GH, Bryant SC, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. *Arch Intern Med.* 2007;167(10):1076-82.
30. Legare F, Adekpedjou R, Stacey D, Turcotte S, Kryworuchko J, Graham ID, et al. Interventions for increasing the use of shared decision making by healthcare professionals. *Cochrane Database Syst Rev.* 2018;7:CD006732.

- 1  
2  
3 31. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-  
4 reducing treatments: a randomized trial. *Ann Intern Med.* 2007;146(12):848-56.  
5 32. Adarkwah CC, Jegan N, Heinzl-Gutenbrunner M, Kuhne F, Siebert U, Popert U, et al. Time-  
6 to-event versus ten-year-absolute-risk in cardiovascular risk prevention - does it make a difference?  
7 Results from the Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. *BMC Med*  
8 *Inform Decis Mak.* 2016;16(1):152.  
9 33. Krones T, Keller H, Sonnichsen A, Sadowski EM, Baum E, Wegscheider K, et al. Absolute  
10 cardiovascular disease risk and shared decision making in primary care: a randomized controlled  
11 trial. *Ann Fam Med.* 2008;6(3):218-27.  
12 34. Fried TR, Tinetti ME, Towle V, O'Leary JR, Iannone L. Effects of benefits and harms on older  
13 persons' willingness to take medication for primary cardiovascular prevention. *Arch Intern Med.*  
14 2011;171(10):923-8.  
15 35. Wouters H, Van Dijk L, Geers HC, Winters NA, Van Geffen EC, Stiggelbout AM, et al.  
16 Understanding Statin Non-Adherence: Knowing Which Perceptions and Experiences Matter to  
17 Different Patients. *PLoS One.* 2016;11(1):e0146272.  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Figure Legends:  
4

5 Figure 1: Participant flow during the trial  
6

7  
8 Figure 2: DCS at 1 month and Kruskal-Wallis analysis of variance and pos-hoc Wilcoxon-  
9  
10 rank sum t-test. Boxes denote the median (25<sup>th</sup>-75<sup>th</sup> percentiles). Whiskers denote the 25<sup>th</sup>  
11  
12 percentile-1.5\*(Inter-Quartile Range) and the 75<sup>th</sup> percentile + 1.5(Inter Quartile Range).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Tables:

**Table 1:** Baseline characteristics

	Control-group	iAR-group	iLE-group
	n=101	n=101	n=101
Age	66(59-70)	66(58-71)	64(59-71)
Gender (male)	86%	82%	85%
More than one CVD location	11%	10%	10%
Current Smoker	17%	16%	9%
Years clinically manifest CVD	0(0-10)	0(0-10)	3(0-10)
Diabetes Mellitus	14%	27%	23%
LDL-cholesterol (mmol/L)	2.0(1.7-2.4)	2.0(1.6-2.4)	2.0(1.6-2.5)
LDL-cholesterol > 1.8 mmol/L	65%	67%	60%
Already on maximum statin therapy	1.3%	1.0%	1.0%
Creatinin (umol/L)	84(78-93)	83(75-96)	85(75-94)
Systolic blood pressure (mmHg)	131(121-142)	131(121-143)	129(122-142)
Number of medications per day	5(4-6)	6(4-9)	6(4-8)
Disutility score	61(9-97)	61(5-97)	61(9-97)
Adequate health literacy	83%	83%	81%

**Legend:** Data are reported as mean  $\pm$  SD, median (interquartile range) or (%). CVD locations defined as coronary artery disease, peripheral artery disease, or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy was based on the Newest Vital Sign score in the baseline questionnaire(28). Disutility is months required to offset inconvenience of daily pill-taking of an idealized medication.(8) Number of medications excludes over the counter medications, (nasal) sprays, and topical medications. Maximum therapy was atorvastatin 80 mg.

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60


For peer review only



**Table 2:** Patient Reported Secondary Outcomes

	Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)			p-value
	Control-group	iAR-group	iLE-group	
DCS (6)	25(16-38)	22(9-29)	25(7-31)	p=0.10*
Brief-IPQ (1)	36(26-42)	34(28-44)	37(30-42)	p=0.68
Brief-IPQ (6)	34(26-43)	35(30-41)	37(29-44)	p=0.19
PAM (1)	60(51-70)	58(53-68)	63(56-75)	p=0.20
PAM (6)	64(54-77)	63(56-77)	63(56-78)	p=0.48
Perceived Statin Efficacy (1)	8(7-9)	8(7-9)	8(7-9)	p=0.92*
Perceived Statin Efficacy (6)	8(7-9)	8(7-9)	8(7-9)	p=0.98*
Understanding of therapy-effects (1)	88(75-88)	88(75-100)	88(75-100)	p=0.07*
Understanding of therapy-effects (6)	88(75-100)	88(75-100)	88(63-100)	p=0.60*
BMQ Adherence Risk Scale (1)	1(0-1)	1(0-1)	1(0-1)	p=0.60*
BMQ Adherence Risk Scale (6)	1(0-1)	1(0-1)	1(0-1)	p=0.41*
SDMQ9 (1); Reported visiting GP (n)	44(9-69); (46)	42(18-62);	58(22-76); (55)	p=0.40*
SDMQ9 (6); reported visiting GP (n)	44(24-73); (60)	48(32-63);	62(22-84); (47)	p=0.28*
RAND-36 Quality of life (6)				
Physical functioning	80(70-85)	75(60-85)	80(65-85)	p=0.11*
Role limitations due to physical health	80(70-85)	75(60-85)	80(65-85)	p=0.57*
Role limitations due to emotional problems	100(100-100)	100(100-100)	100(100-100)	p=0.80*
Energy/fatigue	75(65-80)	70(60-80)	73(55-80)	p=0.20*
Emotional well-being	84(73-92)	84(72-92)	80(72-88)	p=0.11*
Social Functioning	88(75-88)	88(63-88)	88(75-88)	p=0.49*
Pain	90(78-100)	90(68-100)	100(78-100)	p=0.93*
General health	70(55-75)	60(49-75)	65(50-74)	p=0.10*

Legend: Data are for one (1) or six (6) months. Bonferroni p-value for significance was 0.002. \* Denotes a non-parametric test was applied.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41




Figure 2

268x169mm (72 x 72 DPI)

## Supplement

### Supplement 1 (A, B, and C):

The following examples are for a 55-year-old non-smoking non-diabetic Dutch male, with a history of coronary heart disease systolic blood pressure of 140 mmHg, a total cholesterol of 6.0 mmol/L, a creatinine of 93 umol/L, and LDL-cholesterol of 3.4 mmol/L. The patient currently uses atorvastatin 40 mg. *Disclaimer: These examples are for a fictionalized, hypothetical patient and not based on any actual individual.*

### Supplement 1A: Anonymous example of standard-care.

Cholesterol:

Prevention program findings

The concentration of cholesterol in your blood is elevated. An elevated cholesterol level can increase the atherosclerotic process, or the accumulation of cholesterol and other deposits in the walls of your blood vessels.

Advice from the vascular team:

You are already being treated with a cholesterol lowering medication. Yet, your cholesterol level is still elevated. We therefore recommend adjusting the dose of your cholesterol lowering medication or switching to different cholesterol lowering medication. Talk to your doctor about considering this switch.

You can find more information about cholesterol and other risk factors on the internet: [www.cholesterol.nl](http://www.cholesterol.nl), [www.hartstichting.nl](http://www.hartstichting.nl), [www.voedingscentrum.nl](http://www.voedingscentrum.nl) and [www.vaatcentrum.nl](http://www.vaatcentrum.nl).

**Supplement 1B: Example of a ‘personal health profile’ for a hypothetical patient in the individualized absolute risk arm. *Disclaimer: This is a fictionalized, hypothetical patient***

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**My Personal Health Profile**

Part of the SMART-INFORM study

In this folder you will find your personal health profile, which we have made as part of your participation in the SMART-INFORM study. Elements of your medical status were used to complete the profile.

**VIDEOS MADE FOR YOU**

In this envelope, you will find six short videos designed to give you a bit of background information about this health profile and cardiovascular disease in general. The six videos are:

1. What is cardiovascular disease?
2. What is cholesterol?
3. What does a statin do?
4. Do statins have side-effects?
5. How do I read my personal health profile
6. What now?

The videos have been loaded onto the USB-card you are receiving with this Health Profile. You can watch the videos by plugging the USB card into a computer.

**PERSONAL HEALTH PROFILE**

Mr. J. Smith 73 years old	Type of cardiovascular disease Heart
You are a non-smoker	Creatinine-level (Kidney function) 100 umol/L
Blood pressure 140 / 90 mmHg	Prescribed statin Simvastatin 40 mg
Total cholesterol 4.7 mmol/L	You do not have diabetes
You do not report having atrial fibrillation (a type of abnormal heart rhythm)	You do not report having heart-failure

In order to calculate how statin medication effects your prognosis, we used the aspects of your profile listed above. We have based these aspects on the medical records on-file at the hospital.

2

**10-YEAR RISK**

A 10-year risk estimates the chance that you will suffer a heart attack, stroke, or sudden death with the next 10 years. We have estimated your 10-year risk in three different situations from which you can choose.

**THREE SITUATIONS FROM WHICH TO CHOOSE**

You can choose from the following three situations:

1. Continue with your current statin and dose, this is your current prognosis.
2. Stop taking your statin.
3. Increase your statin effectiveness by taking the highest dose of the strongest statin (atorvastatin 80mg).

**1. CONTINUE**



If you continue on your current statin and dose, your 10-year risk will be **21 %**

**2. STOP**



If you stop taking your statin, your 10-year risk will be **29 %**

**3. INCREASE**



If you increase your statin dose, your 10-year risk will be **18 %**

3

**QUESTIONS?**

If you have any questions about the SMART-INFORM study you can contact the investigators. They can be reached on weekdays on 000 00 000 00.

**WE WILL CONTACT YOU**

Within a few weeks, a researcher will be in contact with you to answer any additional questions or provide additional explanation regarding the personal health profile.



4

## Supplement 1C: Example of a 'personal health profile' for a hypothetical patient in the individualized life-expectancy arm. *Disclaimer: This is a fictionalized, hypothetical patient*



### My Personal Health Profile

Part of the SMART-INFORM study

In this folder you will find your personal health profile, which we have made as part of your participation in the SMART-INFORM study. Elements of your medical status were used to complete the profile.

### VIDEOS MADE FOR YOU

In this envelope, you will find six short videos designed to give you a bit of background information about this health profile and cardiovascular disease in general. The six videos are:

1. What is cardiovascular disease?
2. What is cholesterol?
3. What does a statin do?
4. Do statins have side-effects?
5. How do I read my personal health profile
6. What now?

The videos have been loaded onto the USB-card you are receiving with this Health Profile. You can watch the videos by plugging the USB card into a computer.

### PERSONAL HEALTH PROFILE

Mr. J. Smith 73 years old	Type of cardiovascular disease Heart
You are a non-smoker	Creatinine-level (Kidney function) 100 umol/L
Blood pressure 140 / 90 mmHg	Prescribed statin Simvastatin 40 mg
Total cholesterol 4.7 mmol/L	You do not have diabetes
You do not report having atrial fibrillation (a type of abnormal heart rhythm)	You do not report having heart-failure

In order to calculate how statin medication affects your prognosis, we used the aspects of your profile listed above. We have based these aspects on the medical records on-file at the hospital.

2

### DISEASE-FREE LIFE EXPECTANCY

The disease-free life-expectancy indicates how long you can expect to live without having a heart attack, stroke, or sudden death. We have estimated your disease-free life expectancy in three different situations from which you can choose.

### THREE SITUATIONS FROM WHICH TO CHOOSE

You can choose from the following three situations:

1. Continue with your current statin and dose, this is your current prognosis.
2. Stop taking your statin.
3. Increase your statin effectiveness by taking the highest dose of the strongest statin (atorvastatin 80mg).

#### 1. CONTINUE

If you continue with your current statin and dose, your disease-free life-expectancy is **76 years**

#### 2. STOP

If you stop taking your statin, your disease-free life-expectancy will be **22 months shorter**

#### 3. INCREASE

If you increase your statin dose, your disease-free life-expectancy will be **9 months longer**

3

### QUESTIONS?

If you have any questions about the SMART-INFORM study you can contact the investigators. They can be reached on weekdays on 000 00 000 00.

### WE WILL CONTACT YOU

Within a few weeks, a researcher will be in contact with you to answer any additional questions or provide additional explanation regarding the personal health profile.



4

### Supplement 2: Telephone consultation


Short motivational telephone consultation following a structured interview asking the following questions:

- Did you receive the information?
- Have you been able to watch the videos?
- Did you understand all the information?
- Which questions did you have after studying the information?
- Did you already decide which statin treatment option you prefer?
- If yes, did you discuss this with your physician?

### Supplement 3: Visual analogue scale

#### Estimation of therapy-effects

How great do you think the beneficial effects of your cholesterol lowering statin therapy are for you? Circle one number on the scale Below. A zero "0" means you believe that this medication is NOT effective for you and a ten "10" means you believe that is medication is VERY effective for you.



**Supplement 4: Patient questionnaire to assess statin knowledge**

---

What do you know about medication?

---

Below are a number of statements with answer choices. Please circle the answer choice which you believe is correct. If you do not know the correct answer, you can mark 'I don't know'

**Where in the body can you get cardiovascular disease?**

- heart                       legs                       both                       I don't know

Possible side-effects of statins is/are

- muscle pain                       breathing problems                       neither one                       I don't know

**A high cholesterol gives a greater risk of**

- stomach bleeds                       muscle or joint pain                       stroke/heart-attack                       I don't know

**By using statins, I reduce my risk of**

- stomach bleeds                       pneumonias                       heart-attacks                       I don't know

Due to the use of statins, the cholesterol levels in my blood will

- increase                       decrease                       stay the same                       I don't know

**Through the use I statins, I reduce**

- the fatty plaques in my arteries                       my blood pressure                       both                       I don't know

**How long are people usually advised to use statins?**

- for life                       0-1 years                       1-10 years                       I don't know

**How does cholesterol get into to blood?**

- My body produces cholesterol                       I get it from my food                       Both answers are correct                       I don't know



**Supplement 5: Secondary outcomes score ranges**

Scores on the IPQ range from 0 (non-threatening) to 80 (very threatening). Patient Activation Measure (PAM-13) scores range from 0 (low activation) to 100 (high activation). Perceived statin efficacy ranged from 0 (statins perceived as ineffective) to 10 (high level of statin effectiveness). The 9-item shared decision-making questionnaire ranged from 0 (poor shared decision-making) to 100 (optimal shared decision-making). BMQ Adherence Risk Scale ranged from 0 (no self-reported non-adherence) to 4 (self-reported non-adherence). Understanding of statin-therapy ranges from 0 (no answer correct) to 100 (all answers correct). RAND Medical Outcomes Study Short Form Survey (SF-36) questionnaire ranges from 0 (low quality of life) to 100 (high quality of life).

**Supplement 6: General practitioner questionnaire**

	Definitely not (1)	Probably not (2)	Uncertain (3)	Probably yes (4)	Definitely yes (5)
1. How convinced are you that a statin is worthwhile for this patient?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Do you think the patient could benefit from a greater statin dose?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Would you consider statin discontinuation in this patient if the guidelines allowed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The following three questions are only applicable if the patient was part of an intervention arm.					
4. How probable is it that you would use this information to aid in doctor-patient communication?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Do you think the consultation would be more efficient if you had this information beforehand?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Do you think this information would encourage therapy-adherence?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Legend:** Questions 1-3 were asked of every GP. Questions 4-6 were additionally asked for physicians with patients randomized to the individualized absolute risk or the individualized life-expectancy groups.

**Supplement table 1:** Baseline characteristics per missing and non-missing for primary outcome

	Control		iPOL		iARR	
	Non-missing	Missing	Non-missing	Missing	Non-missing	Missing
Population	n=90	n=11	N=87	N=14	N=83	N = 18
Age	64 (59 - 72)	62 (60 - 67)	66 (59-71)	68 (59-73)	66 (59-72)	63 (59 – 68)
Gender (male)	77 (85%)	9 (82%)	72 ( 83%)	11 (79%)	71 (86%)	16 (89%)
One CVD location	79 (88%)	10 (91%)	77 (89%)	14 (100%)	75 (90%)	15 (83%)
Current smokers	13 (16%)	4 (22%)	9 (10%)	1 (9%)	9 (10%)	1 (9%)
Years clinically manifest CVD	5 (0 - 11)	0 (0 - 12)	5 (0-10)	0 (0-2)	0 (0-10)	6 (0-12)
Diabetes Mellitus	19 (21%)	4 (36%)	24 (28%)	3 (21%)	13 (16%)	1 (6%)
LDL-c (mmol/L)	2.0 (1.6 - 2.5)	1.8 (1.6 - 2.4)	2.1 (1.7 - 2.4)	1.7 (1.6 - 2.1)	2.0 (1.6 - 2.4)	2.0 (1.7 - 2.3)
LDL-c >1.8mmol/L	56 (62%)	5 (50%)	62 (71%)	6 (43%)	55 (66%)	11 (61%)
Creatinine (umol/L)	85 (75 - 92)	85 (74 - 97)	82 (74 – 96)	91 (80 – 106)	83 (78 – 95)	85 (80 – 90)
Systolic blood pressure (mmHg)	129 (122 - 142)	132 (116 - 150)	132 (121- 145)	129 (120- 132)	130 (121 - 140)	140 (124- 148)
Number of medications per day	5 (4 - 7)	7 (5 - 10)	6 (4-9)	7 (6-8)	5 (4 - 7)	5 (4 - 6)
Months required to offset disutility of daily pill-taking	42 (9 - 97)	97 (35 - 97)	61 (3 – 97)	97 (70 – 97)	61 (9-97)	12 (9-61)
High likelihood limited literacy	6 (7%)	2 (18%)	6 (7%)	2 (14%)	5 (4%)	4 (22%)
Possibility of limited literacy	9 (10%)	2 (18%)	7 (8%)	2 (14%)	7 (9%)	1 (56%)
Adequate literacy	75 (83%)	7 (63%)	74 (85%)	10 (71%)	70 (85%)	13 (72%)

**Legend:** Data are reported as median (interquartile range) or n (%). CVD locations defined as coronary artery disease, peripheral artery disease, or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy based on the Newest Vital Sign baseline questionnaire.<sup>(32)</sup> Number of medications excludes over the counter medications, (nasal) sprays, and topical medications.

**Supplemental table 2:** Physician reported secondary outcomes

	Median (IQR)			Two-sided p-value
	Control-group	iAR-group	iLE-group	
<b>Post-interventional LDL-c</b>				
LDL-c values determined	n=55	n=43	n=43	
No LDL-c values determined	n=27	n=42	n=42	
Unknown**	n=19	n=21	n=16	
Post-interventional LDL-c at 6 months (mmol/L)	1.9 (1.6 - 2.3)	1.9 (1.4 - 2.3)	1.9 (1.5 - 2.4)	p=0.60
<b>Physician opinion of intervention</b>				
Approached	n=93	n=88	n=87	
Participated	n=51	n=48	n=42	
Convinced that a statin is worthwhile for the patient*	5 (4-5)	5 (5-5)	5 (5-5)	p=0.50
Believes patient could use a higher dose*	3 (2-4)	3 (2-4)	3 (2-4)	† p=0.11
Would consider statin discontinuation if guidelines allowed*	2 (1-3)	2 (1-4)	2 (1-4)	† p=0.84
How probable to use information†*	N/A	4 (4-5)	4 (3-5)	† p=0.84
Believes that consultation would be more efficient†*	N/A	4 (3-5)	4 (3-5)	p=0.4
Believes that information would encourage therapy adherence†*	N/A	4 (3-5)	4 (3-4)	p=0.50

**Legend:** Data are reported as median (interquartile range) or n (%). †Only applicable for the intervention groups LDL-c=low-density lipoprotein cholesterol. Precise questions and answer choices are shown in supplement 6 "General Practitioner Questionnaire."

\*Median numbers of five-point scale where 1 = definitely not, 2= probably not, 3= uncertain, 4= probably yes, 5 = definitely yes.

\*\* No link with dossier from general practitioner possible after six months. † Denotes a non-parametric test was applied.

**Supplemental table 3: Median DCS score per subgroup strata**


	Control –group		iAR –group		iLE –group	
<b>Gender</b> (F=7.02, p-value for interaction=0.32)						
Men	29.7 (19.5 - 42.2)	n=71	23.4 (11.7 - 29.7)	n=72	25.0 (10.9 - 32.8)	n=77
Women	25.8 (21.0 - 47.7)	n=12	14.1 (10.2 - 25)	n=15	26.6 (9.4– 29.7)	n=13
<b>Age</b> (F=0.17, p-value for interaction=0.90)						
>65	19.0 (20.3 - 42.2)	n=45	18.8 (9.0 - 28.6)	n=44	25.0 (8.6 - 31.3)	n=42
≤65	30.0 (19.5 - 42.6)	n=38	23.5 (13.3 - 30.7)	n=43	25.0 (12.9 - 31.6)	n=48
<b>Patient activation measure</b> (F=1.4, p-value for interaction=0.40)						
Low	26.7 (14.8 - 39.1)	n=21	21.9 (3.1 - 25.0)	n=13	26.6 (24.2 - 49.2)	n=15
High	26.7 (25.2 - 42.2)	n=43	23.4 (12.5 - 30.7)	n=43	22.4 (4.7 - 29.7)	n=49
<b>Years since first CVD-event</b> (F=1.4, p-value for interaction=0.24)						
>1 year	29.7 (20.3 - 45.3)	n=33	23.4 (4.7 - 29.7)	n=43	25.0 (14.9 - 33.2)	n=52
≤1 year	26.7 (19.9 - 39.8)	n=50	21.0 (14.1 - 30.0)	n=44	23.5 (5.5 - 33.2)	n=38
<b>Educational level</b> (F=2.8, p-value for interaction=0.09)						
Low	28.1 (25.0 - 37.5)	n=14	6.3 (3.1 - 18.8)	n=17	14.1 (1.6 - 25.0)	n=15
Middle	29.7 (13.3 - 46.1)	n=35	25.0 (16.4 - 30.7)	n=40	25.0 (22.3 - 30.5)	n=38
High	26.6 (20.7 - 41.0)	n=34	21.9 (17.2 - 30.9)	n=30	25.0 (7.8 - 34.4)	n=37
<b>Health literacy*</b> (F=4.0, p-value for interaction=0.02)						
High likelihood limited literacy	50.0 (29.7 - 53.1)	n=5	7.8 (3.1 - 13.7)	n=6	28.1 (25.0 - 31.3)	n=6
Possibility limited literacy	31.2 (25.0 - 41.4)	n=7	29.7 (18.7 - 30.5)	n=7	25.0 (0.0 - 42.1)	n=9
Adequate literacy	26.6 (18.8 - 41.8)	n=70	22.7 (12.9 - 29.7)	n=74	23.4 (8.6 - 29.7)	n=75
<b>Disutility</b> (F=0.6, p-value for interaction=0.54)						
Low (<9 months)	26.6 (14.1 - 45.3)	n=23	18.8 (3.1 - 25.0)	n=25	22.7 (9.0 - 25.4)	n=24
Middle (9-97 months)	32.0 (23.4 - 44.5)	n=18	23.4 (20.7 - 28.5)	n=14	27.3 (14.8 - 41.8)	n=26
High (>97 months)	32.0 (25.0 - 43.0)	n=24	17.2 (3.1 - 29.7)	n=31	23.4 (0.39 - 35.0)	n=22

**Legend:** Data are reported as median (25<sup>th</sup> – 75<sup>th</sup> percentile). \*Further analyses for health-literacy are shown in supplemental figure 2. Health literacy based on the Newest Vital Sign.(32).


Supplemental table 4: Sensitivity analyses: Patient Reported Secondary Outcomes corrected for baseline characteristics.

	ANCOVA
	p-value
DCS (1)	p=0.49
DCS (6)	p=0.50
Brief-IPQ (1)	p=0.21
Brief-IPQ (6)	p=0.63
PAM (1)	p=0.39
PAM (6)	p=0.29
Perceived Statin Efficacy (1)	p=0.67
Perceived Statin Efficacy (6)	p=0.44
Understanding of therapy-effects (1)	p=0.16
Understanding of therapy-effects (6)	p=0.60
BMQ Adherence Risk Scale (1)	p=0.382
BMQ Adherence Risk Scale (6)	p=0.32
SDMQ9 (1); Reported visiting GP (n)	p=0.21
SDMQ9 (6); reported visiting GP (n)	p=0.35
RAND-36 Quality of life (6)	
Physical functioning	p=0.12
Role limitations due to physical health	p=0.48
Role limitations due to emotional problems	p=0.69
Energy/fatigue	p=0.86
Emotional well-being	p=0.25
Social Functioning	P = 0.71
Pain	p = 0.53
General health	P = 0.86

Sensitivity analyses for all outcomes at one (1) and six (6) months post intervention corrected for baseline characteristics: gender, age, smoking status, diabetes status, LDL-cholesterol (mmol.L), creatinine (umol/L), disutility score, NVS health literacy, and number of medications used per day



**Supplemental Figure 1:** Therapy-benefit from statin intensification to atorvastatin 80mg for a) iAR arm and b) iLE arm. Loss of benefit from statin discontinuation in c) iAR arm and d) iLE arm. In the iAR group, the median baseline 10-year absolute CVD risk was 37.6% (28.1-49.0). The estimated absolute 10-year risk change was -2.4% (-1.2 to -3.9) after intensification and 10.2% (7.7- 13.5) after discontinuation. In the iLE group, the median CVD-free life-expectancy was 75.4 years (73.0-82.7). The median change in CVD-free life-years was 0.5 years (0.3 – 0.8) after intensification and -2.0 years (- 1.3 - - 2.8) after discontinuation.



**Supplemental figure 2:** Subgroup analysis. Box-and-whisker plot depict the decisional conflict score at one month stratified by baseline health literacy. The colored boxes denote the median (25th – 75th percentiles). Whiskers denote the 25th percentile-1.5\*(Inter-Quartile Range) and the 75th percentile + 1.5(Inter Quartile Range) in whiskers.



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	2
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2/3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6/7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7/8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9-10 manuscript and in supplemental material
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	10/11
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	6
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	6



1	Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	6
2				
3	Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	6, more details in 10
4		11b	If relevant, description of the similarity of interventions	7/8
5	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	11
6		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	11
7				
8				
9	<b>Results</b>			
10	Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12 and figure 1
11		13b	For each group, losses and exclusions after randomisation, together with reasons	Page 12, figures 1 and supplemental table 1
12				
13				
14				
15				
16				
17				
18	Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
19		14b	Why the trial ended or was stopped	12
20				
21	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1, supplemental table 1
22				
23				
24				
25	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Page 12. Figure 1.
26				
27	Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Figure 2, table 2
28		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA
29				
30	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Pg 14, supplemental table 4
31				
32				
33				
34				
35	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA
36				
37	<b>Discussion</b>			
38	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Pg 16
39				
40	Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Pg 16
41	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Pg 14-17
42				

1	<b>Other information</b>			
2	Registration	23	Registration number and name of trial registry	Pg 6
3	Protocol	24	Where the full trial protocol can be accessed, if available	Pg 18
4	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Pg 18

7 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also  
8 recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.  
9 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

For peer review only

# BMJ Open

## Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial.

Journal:	<i>BMJ Open</i>
Manuscript ID	bmjopen-2020-041673.R2
Article Type:	Original research
Date Submitted by the Author:	22-May-2021
Complete List of Authors:	Jaspers, Nicole; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine Visseren, Frank; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine van der Graaf, Yolanda; Utrecht University, Julius Center for Health Sciences and Primary Care Smulders, Yvo; Vrije Universiteit Amsterdam, University Medical Centre, department of internal medicine Damman, Olga; Amsterdam UMC, Department of Public and Occupational Health, Amsterdam Public Health research institute Brouwers, Corline; Amsterdam UMC Location AMC, Department of Public and Occupational Health, Amsterdam Public Health research institute Rutten, Guy; UMC Utrecht, ) Julius Center for Health Sciences and Primary Care Dorresteijn, Jannick; Utrecht University, University Medical Center Utrecht, Department of Vascular Medicine
<b>Primary Subject Heading</b>:	Cardiovascular medicine
Secondary Subject Heading:	Patient-centred medicine, General practice / Family practice, Communication
Keywords:	Vascular medicine < INTERNAL MEDICINE, PUBLIC HEALTH, Cardiology < INTERNAL MEDICINE, PREVENTIVE MEDICINE, Lipid disorders < DIABETES & ENDOCRINOLOGY

SCHOLARONE™  
Manuscripts



I, the Submitting Author has the right to grant and does grant on behalf of all authors of the Work (as defined in the below author licence), an exclusive licence and/or a non-exclusive licence for contributions from authors who are: i) UK Crown employees; ii) where BMJ has agreed a CC-BY licence shall apply, and/or iii) in accordance with the terms applicable for US Federal Government officers or employees acting as part of their official duties; on a worldwide, perpetual, irrevocable, royalty-free basis to BMJ Publishing Group Ltd ("BMJ") its licensees and where the relevant Journal is co-owned by BMJ to the co-owners of the Journal, to publish the Work in this journal and any other BMJ products and to exploit all rights, as set out in our [licence](#).

The Submitting Author accepts and understands that any supply made under these terms is made by BMJ to the Submitting Author unless you are acting as an employee on behalf of your employer or a postgraduate student of an affiliated institution which is paying any applicable article publishing charge ("APC") for Open Access articles. Where the Submitting Author wishes to make the Work available on an Open Access basis (and intends to pay the relevant APC), the terms of reuse of such Open Access shall be governed by a Creative Commons licence – details of these licences and which [Creative Commons](#) licence will apply to this Work are set out in our licence referred to above.

Other than as permitted in any relevant BMJ Author's Self Archiving Policies, I confirm this Work has not been accepted for publication elsewhere, is not being considered for publication elsewhere and does not duplicate material already published. I confirm all authors consent to publication of this Work and authorise the granting of this licence.

1  
2  
3 Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-  
4 expectancy: does it improve decisional conflict? Three-armed, blinded, randomised  
5  
6 controlled trial.  
7  
8  
9

10  
11  
12 Authors:

13  
14 Nicole E.M. Jaspers<sup>1</sup>, Frank L.J. Visseren,<sup>1</sup> Yolanda van der Graaf,<sup>2</sup> Yvo M. Smulders<sup>3</sup>, Olga

15  
16 C. Damman<sup>4</sup>, C. Brouwers<sup>4</sup>, Guy E.H.M. Rutten<sup>2</sup>, Jannick A.N. Dorresteijn<sup>1</sup>

17  
18 (1) 1. Utrecht University, University Medical Center Utrecht, Department of Vascular  
19  
20  
21 Medicine

22  
23 Utrecht, Utrecht, NL

24  
25 (2) Utrecht University, Julius Center for Health Sciences and Primary Care

26  
27 Utrecht, Utrecht, NL

28  
29 (3) Vrije Universiteit Amsterdam, University Medical Centre, department of internal  
30  
31  
32 medicine, Amsterdam, Noord-Holland, NL

33  
34 (4) Amsterdam UMC, location AMC, Department of Public and Occupational Health,  
35  
36  
37 Amsterdam Public Health research institute Amsterdam, Noord-Holland, NL

38  
39  
40  
41  
42  
43  
44 **Corresponding author**

45  
46 J.A.N. Dorresteijn

47  
48 Department of Vascular Medicine, University Medical Centre Utrecht

49  
50 PO Box 85500, 3508 GA Utrecht, The Netherlands

51  
52 Phone: +31 (0)88 7555161; Fax: +31 (0)30 2523741

53  
54  
55 Email: j.a.n.dorresteijn-2@umcutrecht.nl  
56  
57  
58  
59  
60

## Abstract

**Objective:** To determine whether communicating personalized statin therapy-effects obtained by prognostic algorithm leads to lower decisional conflict associated with statin use among patients with stable cardiovascular disease (CVD) compared to standard (non-personalized) effects.

**Design:** Hypothesis-blinded, three-armed randomized controlled trial

**Setting and participants:** 303 statin-users with stable CVD enrolled in a cohort

**Intervention:** Participants were randomized in a 1:1:1 ratio to standard (non-personalized) practice (control-group) or one of two intervention arms. Intervention arms received standard practice plus 1) a *personalized health profile*, 2) educational videos, and 3) a structured telephone consultation. Intervention arms received personalized estimates of prognostic changes associated with both discontinuation of current statin and intensification to the most potent statin type and dose (i.e. atorvastatin 80 mg). Intervention arms differed in how these changes were expressed: either change in 10-year absolute CVD risk (iAR-group) or CVD-free life-expectancy (iLE-group) calculated with the SMART-REACH model (<http://U-Prevent.com>).

**Outcome:** Primary outcome was patient decisional conflict score (DCS) after one-month. The score varies from 0 (no conflict) to 100 (high conflict). Secondary outcomes were collected at one or six months: DCS, quality of life, illness perception, patient activation, patient perception of statin efficacy and shared decision-making, self-reported statin adherence, understanding of statin-therapy, post-randomization low-density lipoprotein cholesterol (LDL-c) level, and physician opinion of the intervention. Outcomes are reported as median (25<sup>th</sup> – 75<sup>th</sup> percentile).

1  
2  
3 **Results:** Decisional conflict differed between the intervention arms: median control 27 (20-  
4 43), iAR-group 22 (11-30; p-value versus control 0.002), and iLE-group 25 (10–31; p-value  
5 versus control 0.02). No differences in secondary outcomes were observed.  
6  
7  
8

9  
10 **Conclusion:** In patients with clinically manifest CVD, providing personalized estimations of  
11 treatment-effects resulted in a small but significantly lower decisional conflict after one  
12 month. The results support the use of personalized predictions for supporting decision-  
13 making.  
14  
15  
16  
17  
18

19 **Registration:** Netherlands Trial Registry (Identifier NTR6227/NL6080)  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

### Strengths and limitations of the study

- Patients were provided with estimations of their personalized causal therapy-effects, unlike many previous studies which used hypothetical therapy-effects.
- Performance bias was limited by hypothesis blinding.
- Because the control group reported a low decisional conflict and a high confidence in stating medication, the effect seen in the study is possibly underestimated compared to the general population,
- The personalized effects were not used directly during a clinical consultation, but provided prior to any potential consultation with a physician.
- Some questionnaires were created for this study and were not externally validated.



## Introduction

Several online tools have recently become available which can calculate the personalized therapy effects for various cardiovascular disease (CVD) prevention strategies. Such calculators can express the therapy-benefit in terms absolute 10-year CVD risk reduction, or in recent years, gain in healthy life-expectancy.<sup>1</sup>

The use of decision tools is associated with increased knowledge and less decisional conflict, and providing therapy-related information increases patient participation in medical decision-making.<sup>1-5</sup> However, most decision aids do not provide personalized benefits and harms.<sup>6</sup>

Rather, most investigated patient decision-aids use hypothetical or population-based effects of CVD-prevention and not the actual, personalized causal effects an individual can expect.

One obstacle in providing these causal effects however, is that patients often desire a far greater therapy-benefit than can be expected from preventive therapy.<sup>7-9</sup> One survey showed that patients desire an increase in life-expectancy of around 42 months from life-long statin-use whereas the actual benefit is often less than half this amount.<sup>7 8</sup> Being presented with an actual predicted therapy-benefit far smaller than the benefit desired might discourage patients from using medication. Moreover, metrics to used communicate therapy-effects elicit different opinions on the value of preventive therapy, motivation to use therapy, and possibly therapy-adherence.<sup>10-13</sup>

We conducted a hypothesis blinded, three-armed, randomized controlled trial (RCT) to determine whether communication strategies involving personalized therapy-effects of statin therapy obtained by algorithm, expressed as change in CVD-free life-expectancy or absolute 10-year CVD-risk reduction, lead to improved decisional certainty about the use of statins compared to standard communication strategies and compared to one another.

## Methods

### Population

The SMART-Inform study was nested within the previously described Secondary Manifestations of ARterial disease (SMART) study, an ongoing, single-center, prospective cohort of patients referred to the University Medical Center Utrecht in the Netherlands for CVD screening.<sup>14</sup> All patients invited to participate in a SMART-examination were telephonically informed of the SMART-Inform sub-study and sent further information about by mail. Additional inclusion criteria for SMART-Inform were current statin use, being between 45-80 years old, and having CVD (i.e. coronary artery disease, cerebrovascular disease, and peripheral artery disease and abdominal aortic aneurysm). Additional exclusion criteria for SMART-Inform were terminal malignancy and not returning the baseline questionnaires.

### Design, blinding, and randomization

The SMART-Inform study was a three-armed, hypothesis-blinded, RCT. Hypothesis blinding entailed informing patients and their general practitioners (GPs) that all patients would receive at least standard SMART-protocol practice and that the study goal was to investigate if information about cholesterol-lowering medications would impact motivation for use. Patients were unaware what aspect of the received content was additional to standard practice, and what the primary and secondary outcomes were. Researchers and outcome assessors were not blinded. A computer generated random allocation sequence was used to assign each patient after inclusion by order of inclusion. The investigator generating the random sequence was not involved in other aspects of the study. All other investigators had no access to the sequence.

### Ethics Statement and Registration

1  
2  
3 The Medical Ethics Review Committee of the UMCU approved the study (16-665/D). All  
4 participants provided written informed consent. The study was registered in the Netherlands  
5  
6  
7  
8 Trial Registry (Identifier NTR6227 and NL6080).  
9

### 10 11 12 **Patient and public involvement**

13  
14 The study design and goal was discussed at an open conference of patient-organizations held  
15 in Amstelveen, the Netherlands in April 2016 to gain and incorporate input from patients at  
16  
17  
18 an early stage.  
19  
20  
21

### 22 23 24 **Description of standard practice**

25  
26 All participants received cardiovascular care as usual from their own referring GP or medical  
27  
28 specialist and written information consisting of general lifestyle advice based on the  
29  
30 treatment targets recommended by the European Society of Cardiology (SMART-study  
31  
32 standard practice supplement 1A).<sup>15</sup>  
33  
34  
35

### 36 37 38 **Description of intervention arms**

39  
40 There were three intervention arms: the control group, the 10-year risk (iAR-group) and  
41  
42 CVD-free life-expectancy (iLE-group). The control group received only standard practice.  
43  
44 Both intervention arms received standard practice plus: 1) a leaflet entitled *personalized*  
45  
46 *health profile* (supplement 1B and 1C for two fictional patients); 2) a USB device containing  
47  
48 educational videos; 3) a structured telephone consultation enforcing uptake of the information  
49  
50 (supplement 2). The *'personal health profile'* outlined the individual effect of the following  
51  
52 treatment options: 1) continue with the type and dose of statin-therapy ('current prognosis');  
53  
54 2) discontinue statin therapy ('stop statins'); 3) intensify to maximum statin-therapy, defined  
55  
56 as once-daily atorvastatin 80 mg ('increase statins'). The only difference between the  
57  
58  
59  
60

1  
2  
3 intervention arms was the measure used to communicate the prognostic change associated  
4  
5 with the therapy-effects; individual treatment effects were estimated in terms of change in 10-  
6  
7 year risk (iAR-group) or CVD-free life-expectancy (iLE-group). The USB-device contained  
8  
9 intervention-group specific educational videos on how to read and interpret the '*personal*  
10  
11 *health profile*' and the effect of statin-medications on CVD. The structured telephone  
12  
13 consultation for the intervention arms ensured the information was well-received and  
14  
15 understood by the patients. In the SMART-study, patients are encouraged to discuss the  
16  
17 results with their own doctor and decide whether or not to change their statin prescription.  
18  
19 Participants were free to decide whether to follow this advice or not. In the SMART-Inform  
20  
21 study, the received information was not designed to replace a doctor's advice and there was  
22  
23 no extra face-to-face contact; however, all patients were strongly encouraged to visit their GP  
24  
25 within two weeks to discuss the received information. Follow-up questionnaires were sent by  
26  
27 mail one and six months post-intervention, with telephone reminders ensuing after two weeks  
28  
29 if the questionnaires were not returned.  
30  
31  
32  
33  
34  
35  
36  
37

### 38 **Predicted therapy-effects**

39  
40 The estimations in the '*personal health profile*' were obtained with the SMART-REACH  
41  
42 score, an internationally validated model predicting the personalized effects of secondary  
43  
44 CVD-prevention for patients aged 45-80 years (<http://U-Prevent.com>).<sup>2</sup> The model combines  
45  
46 hazard ratio's derived from meta-analyses with a prediction algorithm incorporating  
47  
48 individual patient characteristics to derive the personalized therapy effects. A 1 mmol/L  
49  
50 reduction in LDL-c was modelled to correspond to the CVD-specific hazard ratio of 0.80 and  
51  
52 the expected LDL-c -reduction for each statin was derived from a previous meta-analysis.<sup>16 17</sup>  
53  
54 Subgroup analyses in literature provide no evidence for differences of treatment effects on a  
55  
56 relative effect scale for statins. Therefore, the treatment effect estimates based on the  
57  
58  
59  
60

1  
2  
3 SMART-REACH score differ only on an absolute effect scale. Supplemental figure 1 shows  
4  
5 the distribution of the predicted therapy-effects for the trial patients.  
6  
7  
8  
9

### 10 **Primary outcome**

11  
12 The study's primary outcome was the intergroup difference in experienced decisional conflict  
13  
14 at 1 month regarding the decision to continue, discontinue, or intensify statin therapy.

15  
16 Decisional conflict was measured using the Decisional Conflict Scale (DCS), a validated,  
17  
18 translated, measure of patient perception of uncertainty in choosing between options.<sup>18 19</sup> The  
19  
20 DCS consists of 16 statements pertaining to the decision to use statins as prescribed (e.g., "I  
21  
22 am clear about which benefits matter most to me"). The DCS scale measures the amount of  
23  
24 internal conflict a patient feels regarding a medical decision. Summary scores range from 0  
25  
26 (no decisional conflict) to 100 (extremely high decisional conflict). Scores >37.5 are  
27  
28 associated with feeling unsure about implementation of the decision, possibly leading to  
29  
30 discontinuation of the chosen option or fretting about the chosen option (i.e. using statins as  
31  
32 prescribed by the physician), and <25 are associated with following through with a decision.  
33  
34  
35  
36  
37  
38  
39

### 40 **Patient reported secondary outcomes**

41  
42 Secondary outcomes reported only at 6 months were the DCS and quality of life measured  
43  
44 using the eight subscales of the RAND Medical Outcomes Study Short Form Survey (SF-  
45  
46 36).<sup>20</sup> Other patient-reported secondary outcomes were reported at both 1 and 6 months. The  
47  
48 Brief Illness Perception Questionnaire (brief IPQ) was used to measure the degree to which  
49  
50 CVD was considered threatening by patients.<sup>21</sup> A Visual Analog Scale (VAS) was used to  
51  
52 measure how effective patients perceived statin therapy (supplement 3). The thirteen question  
53  
54 Patient Activation Measure (PAM-13) was used to assess patient knowledge, skills, and  
55  
56 confidence for self-management of health.<sup>22</sup> Due to limitations on maximum population size  
57  
58  
59  
60

1  
2  
3 of academic use licenses, PAM-13 was only used for the last 213 study participants. Patient's  
4 perception of shared decision-making was measured with the Shared Decision Making  
5 Questionnaire (SDMQ-9).<sup>23</sup> Self-reported statin adherence was determined with the 2003  
6 Brief Medication Questionnaire (BMQ).<sup>24</sup> Patient understanding of statin-therapy was  
7 measured with a questionnaire developed for the trial (supplement 4). The possible numeric  
8 ranges and interpretation of the secondary outcomes are shown in supplement 5.  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18

### 19 **Physician reported secondary outcomes**

20  
21 Patients' GPs' received a copy of the personalized health profile. Upon enrolment of the first  
22 patient from their practice, GPs were provided a short telephonic explanation of the study and  
23 asked to fill in a questionnaire (supplement 6). Questionnaire results and the last known post-  
24 intervention LDL-value at 6 months were secondary outcomes. Interviewed GPs were  
25 blinded to study outcomes and treatment arm differences. GPs were not approached if they  
26 had subsequent patients included in the study, as receiving material from multiple patients  
27 would have unblinded them to treatment arm differences.  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39

### 40 **Sample size**

41  
42 The aim of this study was a pairwise comparison between study arms. To limit the overall  
43 probability of type 1 errors to 0.05, first an ANOVA was used to detect the presence of any  
44 differences between the three groups. If the ANOVA detected a difference, subsequent T-test  
45 were performed. Therefore, the sample-size was calculated to detect a difference in two  
46 groups using the T-test. Sample-size calculations were conducted using G\*Power version  
47 3.1. Sample size was based on an effect size (Cohen's  $d = \text{mean difference} / \text{standard}$   
48 deviation) of 0.43, a standard deviation of 0.80 to detect a mean difference of 0.34 on the 5-  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 point scale (ranging from 0-4) corresponding to 8.6 on the 100-point scale.<sup>25 26</sup> A power of  
4  
5 80% and a two-tailed alpha of 0.05 was used. A minimum of 86 patients per arm was needed.  
6  
7  
8  
9

### 10 **Statistical analyses**

11  
12 An intention-to-treat-analysis was performed. Differences among the three arms were  
13  
14 detected with ANOVA, or a Kruskal-Wallis one-way ANOVA to deal with  
15  
16 heteroscedasticity. Assumptions of normal (residual) distribution and homoscedasticity were  
17  
18 visually inspected. If ANOVA  $p < 0.05$ , pairwise comparisons between arms were determined  
19  
20 using a t-test or with the Wilcoxon-rank sum test for the difference in ranked means if  
21  
22 ANOVA assumptions were not met after transformation attempts. Analyses were performed  
23  
24 using R-Statistical Software, version 1.0.14.  
25  
26  
27  
28  
29

### 30 **Subgroups**

31  
32 Pre-specified subgroup analyses were performed using an ANCOVA test to investigate  
33  
34 whether the effect of the intervention on DCS at one month differed according to the  
35  
36 following: gender; age (<65 versus >65); years since first CVD event (<1 versus >1 years);  
37  
38 educational level (low, medium or high);<sup>27</sup> low versus high patient activation (low a PAM-13  
39  
40 level of 1-2 and high a PAM-13 level of 3-4 based on a conversion of the 100-point PAM-13  
41  
42 score to a 4-point scale;<sup>22 28</sup> health literacy categories based on the Dutch version of the  
43  
44 Newest Vital Sign (NVS);<sup>29</sup> and disutility defined as the minimum gain in life-expectancy  
45  
46 desired to offset the inconvenience of taking a lifelong, hypothetical, idealised daily tablet.<sup>8</sup>  
47  
48 The study was not powered to detect any subgroup differences. A Bonferroni correction  
49  
50 corresponding to the 22 secondary outcomes was applied; the new p-value for statistical  
51  
52 significance was 0.002.  
53  
54  
55  
56  
57  
58  
59  
60

## Sensitivity analyses

Sensitivity analyses were performed to account for possible differences in baseline characteristics for missing outcomes between trial arms by conducting an ANCOVA with gender, age, smoking status, diabetes status, LDL-cholesterol (mmol/L), creatinine (umol/L), disutility score, NVS health literacy, and number of medications used daily.

## Results

### Participant flow

Between March 2017 and August 2018, 303 participants were enrolled. Baseline characteristics are shown in table 1 and the flow of participants throughout the trial in figure 1. The primary outcome was collected in 260 participants (86%) (control=83, iAR group=87, iLE group=90). Supplemental table 1 displays characteristics for those with and without the primary endpoint. At one-month, 12% (n=10) of control, 8% (n=7) of iAR, and 11% (n=9) of iLE patients reported increasing their statin dose after the intervention. Respective numbers for decreased statin dose were 2% (n=2) in the control arm, 1% (n=1) in the iAR arm, and 3% (n=3) in the iLE arm.

### DCS at one month

There was a significant difference between the groups (ANOVA  $\chi^2$ , p=0.002) with a median (25<sup>th</sup>-75<sup>th</sup> percentile) DCS of 27 (20–43) for control arm, 22 (11–30) for the iAR arm, and 25 (10–31) for iLE arm. Subsequent Wilcoxon-rank sum tests showed the difference between the control and iAR arm (W=2707, p=0.001) and the control and iLE arm (W=4219, p=0.02) to be significant. The difference between iAR and iLE arms was not significant (W=3317, p=0.21, Figure 2). All groups showed a DCS of around 25, the value associated with following through with a decision.



### **Patient reported secondary outcomes**

After 6 months, there was no longer a significant difference between the groups in DCS score (ANOVA  $\chi^2$ ,  $p=0.10$ ) with a median (25<sup>th</sup>-75<sup>th</sup> percentile) DCS of 25 (16–38) for control arm, 22 (9–29) for the iAR arm, and 25 (7–29) for iLE arm. All other secondary outcomes also showed no intergroup differences. There was no difference in how threatening patients perceived their CVD (Brief-IPQ) or how effective patients perceived statin medications (VAS 8) at either 1 or 6 months. There was no difference in PAM, understanding of statin effects, self-reported adherence (BMQ Adherence Scale), or patients' perceptions of shared-decision making between arms (SDMQ9). At six months, quality of life did not differ on any RAND SF-36 subscale (table 2).

### **Physician reported secondary outcomes**

Physician reported secondary outcomes are shown in supplemental table 2. Between randomization and 6 months, 119 patients had their LDL-c values determined (control  $n=51$ , iAR  $n=48$ , iLE= $39$ ), with no difference in median serum LDL-c levels found (median 1.9 mmol/L in all groups) between study-arms. In total, 267 physicians were approached after the inclusion of their first patient of which 141 (53%) participated in the questionnaire. Physicians viewed statin-medication as equally worthwhile for patients in all study-arms. There was no difference of opinion between how iAR and iLE formats could positively influence doctor-patient communication, consultation efficiency, and therapy-adherence.

### **Subgroup analysis**

No evidence of subgroup effects was found for sex ( $p$ -value for interaction = 0.32), age ( $p=0.90$ ), years since first CVD-event ( $p=0.24$ ), months gain in CVD-free life-expectancy desired prior to taking an idealized medication daily (i.e. disutility,  $p=0.54$ ), and educational level ( $p=0.09$ ). An interaction was found for health literacy ( $p = 0.02$ ). The median (25<sup>th</sup>-75<sup>th</sup>

percentile) DCS scores for all subgroups are shown in supplemental table 3, and a t-test for differences in each health literacy group is shown in supplemental figure 2. Across health literacy categories, decisional conflict was lower in the in intervention arms than in the control arm, with the largest differences found in people with a low health literacy.

### **Sensitivity analyses**

Supplemental table 4 shows the sensitivity analyses which corrected for baseline characteristics. After correction none of the outcomes were significant.

### **Discussion**

Providing personalized estimates of the prognostic changes associated with statin use in terms of 10-year CVD risk and CVD-free life-years (compared to a control group) resulted in lower decisional conflict after one month. After six months no differences were found. Likewise, no differences were found in secondary outcomes, which included the degree to which people perceived their CVD to be threatening, how effective patients viewed their statin-medications, and LDL-c levels after six months. Although the actual benefit from CVD-prevention is smaller than people initially report acceptable, communicating the individual benefit resulted in lower decisional conflict, without may people discontinuing their treatments. However, the effect was small in a population with a low baseline DCS. Many tools designed for decision-support report DCS differences of 8-10 points immediately post intervention in favour of the decision-aid.<sup>6</sup> We measured the outcomes after one month to provide time for patients to visit their physician. The already low decisional conflict in the control arm, possibly explaining the relatively small absolute differences in median scores found in this study (2-5 points). The loss of statistical significance at six months, is in line with previous studies investigating the long-term effects of decision-support tools of for statin medications indicating that positive results of such interventions fade over time.<sup>30</sup>

1  
2  
3 The use of patient communication-aids is known to make people feel better informed and  
4 help them form accurate opinions of therapy benefit-harm ratios.<sup>6,31</sup> A number of studies  
5 have examined the effect of providing estimations of hypothetical or generalised therapy-  
6 benefit to patients with clinically manifest CVD.<sup>11,32-34</sup> One study examined the effect of  
7 providing primary care patients without any prior statin-exposure with the approximated  
8 personalized effect of statin medications.<sup>12</sup> Receiving the predictions in the form of absolute  
9 risk reduction estimates resulted in a greater likelihood to redeem statin-medications  
10 compared to prolongation of life. However, no differences were found in patient satisfaction  
11 and decision confidence. A possible explanation for this discrepancy between literature and  
12 our study could be that patients already using medication may respond differently to  
13 personalized estimations than patients initiating a new medication. As opposed to first-time  
14 statin-users, all patients in our study had already been using statins, and may therefore  
15 already know if they have experienced statin-related side-effects. Willingness to take a new  
16 therapy may be more sensitive to the perceived side-effects than the perceived benefits.<sup>35</sup>  
17 Similarly, worry about side-effects is a stronger determinant of intentional non-adherence  
18 than belief in the effectiveness of statin-medications.<sup>36</sup>  
19  
20 Similar to our study, previous literature shows that patients often overestimate the relative  
21 effects of medication and desire a greater absolute therapy-benefit than clinically feasible.<sup>7,8</sup>  
22 Although the majority of patients in our study desired more benefit than clinically feasible  
23 (median disutility score 61 months), statin discontinuation was minimal and there was no  
24 evidence of subgroup effects based on baseline disutility. Although physicians may also over-  
25 estimate the effects of preventive therapy,<sup>7</sup> there were no inter-groups differences in how  
26 physicians perceived the necessity of statin-medications.  
27  
28 Strengths of this study include providing patients with estimations of their actual causal  
29 therapy-effects, in contrast to pre-existing decision aids which present participants with either  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 hypothetical or population-based therapy-effects. As we assessed current statin users, we  
4 were able to provide information on multiple treatment-options. Use of the cohort's standard  
5 procedures allowed for several strengths. Systematically approaching cohort patients who  
6 were already due to receive physical examinations minimized the risk of preferentially  
7 selecting patients likely to respond to personalized predictions. Moreover, it was possible to  
8 select a structured and well-defined control group. The structured telephonic consultations  
9 ensured patients had each interventional format explained in a similar fashion. Performance  
10 bias was limited by hypothesis blinding. A number of study limitations must also be  
11 highlighted. First, the control group of this clinically stable cohort population has low  
12 decisional-conflict and high belief in the effectivity of statin medications. The effects  
13 described here may thus be different in patients who have pre-existing negative associations  
14 with statins due to adverse effects, or who are considering a new, more intensive strategy  
15 with additional medication such as blood pressure reduction or antithrombotic treatment.  
16 Second, the personalized effects were not used directly during a clinical consultation, but  
17 provided prior to any potential consultation with a physician. The effects may therefore be  
18 different compared to a population of patients who are involved in a clinical consultation in  
19 which statin therapy is discussed. Third, the loss to follow-up was 14% for the primary  
20 outcome. This is however lower than other communication-trials involving follow-up  
21 questionnaires<sup>12</sup> and baseline characteristics of missing and non-missing individuals were  
22 relatively similar. Correction for baseline health literacy, a characteristic which may have  
23 differed between missing and non-missing individuals did not level-off the effects. Fourth,  
24 self-reported measures may be subject to recall and reporting biases, in particular for  
25 questions relating to adherence. Fifth, a number of questionnaires were created specific for  
26 this study, and were thus not externally validated.  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 A number of risk-prediction tools capable of estimating treatment-effects for lipid-lowering,  
4 blood pressure-lowering, and anti-thrombotic medications are now readily available in  
5  
6 clinical practice for patients with and without CVD.<sup>1</sup> Statins are usually prescribed to patients  
7  
8 with CVD during hospital admission for the first CVD event. Outpatient decision-making  
9  
10 regarding statins in this population usually pertain to continuing or altering the current statin  
11  
12 dose. In the present study, we aimed to examine a setting closely resembling the outpatient  
13  
14 practice. However, only a small effect was found. Therefore, future studies could focus on  
15  
16 populations with higher baseline decisional conflict such as patients experiencing adverse  
17  
18 effects or considering intensifying preventive treatment with additional medication such as  
19  
20 blood-pressure lowering or antithrombotic treatment.  
21  
22  
23  
24  
25  
26  
27  
28

29 In conclusion, providing statin users with clinically manifest CVD personalized estimations of  
30  
31 treatment-effects, both in terms of 10-year absolute risk and CVD-free life-expectancy,  
32  
33 resulted in small but significantly lower decisional conflict associated with statin use after one  
34  
35 month of follow-up. This effect of the intervention disappeared after 6 months of follow-up.  
36  
37 The results support the use of personalized predictions of absolute therapy benefit in clinical  
38  
39 practice. Future studies may focus on decisions associated with higher decisional conflict such  
40  
41 as the addition of more intensive preventive treatment options on top of standard treatment.  
42  
43  
44  
45  
46  
47

### 48 **Acknowledgements**

49  
50 Participants of the April 2016 Amstelveen PGOSupport conference; SMART research  
51  
52 nurses; R. van Petersen (data-manager); B.G.F. Dinther (cohort manager) and the SMART  
53  
54 Study Group: A. Algra MD,PhD; D.E. Grobbee, MD,PhD; G.J. de Borst, MD,PhD,  
55  
56 Department of Vascular Surgery; L.J. Kappelle, MD,PhD, Department of Neurology; T.  
57  
58  
59  
60

1  
2  
3 Leiner, MD,PhD, Department of Radiology; H.M. Nathoe, MD,PhD, Department of  
4  
5 Cardiology  
6  
7

### 8 **Funding**

9  
10 Partially funded by a Netherlands Heart Foundation grant (2016T026). Funder was not  
11  
12 involved in the design or assessment of the study.  
13  
14  
15

### 16 **Conflict of interest**

17  
18 We have read and understood BMJ policy on declaration of interests and declare that we have  
19  
20 no competing interests.”  
21  
22  
23

### 24 **Transparency declaration**

25  
26 The lead author affirms that this manuscript is an honest, accurate, and transparent account of  
27  
28 the study being reported; that no important aspects of the study have been omitted; and that  
29  
30 any discrepancies from the study as planned (and, if relevant, registered) have been  
31  
32 explained.  
33  
34  
35

### 36 **Author Contributor statement**

37  
38 NEMJ, FLJV, YdG, OCD, CB, JAND contributed to the conception, design of the work and  
39  
40 interpretation of the data, YMS & GEHMR contributed to the interpretation. NEMJ drafted  
41  
42 the work and performed the analyses, FLJV, YdG, OCD, CB, JAND, YMS & GEHMR  
43  
44 critically revised the work, all authors gave final approval and agree to be accountable for the  
45  
46 work.  
47  
48  
49  
50  
51

### 52 **Data sharing statement**

53  
54 Some individual deidentified participant data (including data dictionaries) may be shared  
55  
56 upon reasonable request pending approval by the department and institution on a case-by-  
57  
58  
59  
60

1  
2  
3 case basis. Approval will be based the scientific question to be answered with the data, ability  
4  
5 of the authors of this manuscript to co-operate on the project, and compliance with contracts  
6  
7 acquired for the questionnaires in this study and hospital and SMART-cohort policy.  
8  
9  
10  
11  
12

## 13 References

- 14 1. Jaspers NEM, Ridker PM, Dorresteyn JAN, et al. The prediction of therapy-benefit for individual  
15 cardiovascular disease prevention: rationale, implications, and implementation. *Curr Opin*  
16 *Lipidol* 2018 doi: 10.1097/MOL.0000000000000554
- 17 2. Kaasenbrood L, Bhatt DL, Dorresteyn JAN, et al. Estimated Life Expectancy Without Recurrent  
18 Cardiovascular Events in Patients With Vascular Disease: The SMART-REACH Model. *Journal*  
19 *of the American Heart Association* 2018 7(16) doi:  
20 <https://doi.org/10.1161/JAHA.118.009217>
- 21 3. Lloyd-Jones DM, Huffman MD, Karmali KN, et al. Estimating Longitudinal Risks and Benefits From  
22 Cardiovascular Preventive Therapies Among Medicare Patients: The Million Hearts  
23 Longitudinal ASCVD Risk Assessment Tool: A Special Report From the American Heart  
24 Association and American College of Cardiology. *J Am Coll Cardiol* 2017;69(12):1617-36. doi:  
25 10.1016/j.jacc.2016.10.018
- 26 4. Board JBS. Joint British Societies' consensus recommendations for the prevention of  
27 cardiovascular disease (JBS3). *Heart* 2014;100 Suppl 2:ii1-ii67. doi: 10.1136/heartjnl-2014-  
28 305693
- 29 5. Hoffmann TC, Del Mar C. Patients' expectations of the benefits and harms of treatments,  
30 screening, and tests: a systematic review. *JAMA Intern Med* 2015;175(2):274-86. doi:  
31 10.1001/jamainternmed.2014.6016
- 32 6. Stacey D, Legare F, Lewis K, et al. Decision aids for people facing health treatment or screening  
33 decisions. *Cochrane Database Syst Rev* 2017;4:CD001431. doi:  
34 10.1002/14651858.CD001431.pub5
- 35 7. Jaspers NEM, Visseren FLJ, Numans ME, et al. Variation in minimum desired cardiovascular  
36 disease-free longevity benefit from statin and antihypertensive medications: a cross-  
37 sectional study of patient and primary care physician perspectives. *BMJ Open*  
38 2018;8(5):e021309. doi: 10.1136/bmjopen-2017-021309
- 39 8. Fontana M, Asaria P, Moraldo M, et al. Patient-accessible tool for shared decision making in  
40 cardiovascular primary prevention: balancing longevity benefits against medication disutility.  
41 *Circulation* 2014;129(24):2539-46. doi: 10.1161/CIRCULATIONAHA.113.007595
- 42 9. Trewby PN, Reddy AV, Trewby CS, et al. Are preventive drugs preventive enough? A study of  
43 patients' expectation of benefit from preventive drugs. *Clin Med (Lond)* 2002;2(6):527-33.
- 44 10. Zipkin DA, Umscheid CA, Keating NL, et al. Evidence-based risk communication: a systematic  
45 review. *Ann Intern Med* 2014;161(4):270-80. doi: 10.7326/M14-0295
- 46 11. Jegan NRA, Kurwitz SA, Kramer LK, et al. The effect of a new lifetime-cardiovascular-risk display  
47 on patients' motivation to participate in shared decision-making. *BMC Fam Pract*  
48 2018;19(1):84. doi: 10.1186/s12875-018-0766-x
- 49 12. Harmsen CG, Kristiansen IS, Larsen PV, et al. Communicating risk using absolute risk reduction or  
50 prolongation of life formats: cluster-randomised trial in general practice. *Br J Gen Pract*  
51 2014;64(621):e199-207. doi: 10.3399/bjgp14X677824
- 52 13. Misselbrook D, Armstrong D. Patients' responses to risk information about the benefits of  
53 treating hypertension. *Br J Gen Pract* 2001;51(465):276-9.  
54  
55  
56  
57  
58  
59  
60

14. Simons PC, Algra A, van de Laak MF, et al. Second manifestations of ARterial disease (SMART) study: rationale and design. *Eur J Epidemiol* 1999;15(9):773-81.
15. Piepoli MF, Hoes AW, Agewall S, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice: The Sixth Joint Task Force of the European Society of Cardiology and Other Societies on Cardiovascular Disease Prevention in Clinical Practice (constituted by representatives of 10 societies and by invited experts) Developed with the special contribution of the European Association for Cardiovascular Prevention & Rehabilitation (EACPR). *Eur Heart J* 2016;37(29):2315-81. doi: 10.1093/eurheartj/ehw106
16. Cholesterol Treatment Trialists C, Baigent C, Blackwell L, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. *Lancet* 2010;376(9753):1670-81. doi: 10.1016/S0140-6736(10)61350-5
17. Law MR, Wald NJ, Rudnicka AR. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis. *BMJ* 2003;326(7404):1423. doi: 10.1136/bmj.326.7404.1423
18. O'Connor A. User Manual - Decisional conflict scale 1993 [updated 2010. Available from: [http://decisionaid.ohri.ca/eval\\_dcs.html](http://decisionaid.ohri.ca/eval_dcs.html).
19. O'Connor AM. Validation of a decisional conflict scale. *Med Decis Making* 1995;15(1):25-30.
20. Ware JE, Jr., Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. *Med Care* 1992;30(6):473-83.
21. Broadbent E, Petrie KJ, Main J, et al. The brief illness perception questionnaire. *J Psychosom Res* 2006;60(6):631-7. doi: 10.1016/j.jpsychores.2005.10.020
22. Hibbard JH, Mahoney ER, Stockard J, et al. Development and testing of a short form of the patient activation measure. *Health Serv Res* 2005;40(6 Pt 1):1918-30. doi: 10.1111/j.1475-6773.2005.00438.x
23. Kriston L, Scholl I, Holzel L, et al. The 9-item Shared Decision Making Questionnaire (SDM-Q-9). Development and psychometric properties in a primary care sample. *Patient Educ Couns* 2010;80(1):94-9. doi: 10.1016/j.pec.2009.09.034 [published Online First: 2009 Oct 30]
24. Svarstad BL, Chewning BA, Sleath BL, et al. The Brief Medication Questionnaire: a tool for screening patient adherence and barriers to adherence. *Patient Educ Couns* 1999;37(2):113-24.
25. Schwalm J, Stacey D, Pericak D, Natarajan M. Radial Artery Versus Femoral Artery Access Options in Coronary Angiogram Procedures. *Circulation: Cardiovascular Quality and Outcomes* 2012;5:260-66. doi: 10.1161/CIRCOUTCOMES.111.962837
26. O'Connor AM. Validation of a Decisional Conflict Scale. *Med Decis Making* 1995;15(25) doi: 10.1177/0272989X9501500105
27. Statistiek CBvd. Opleidingsniveau [Available from: <https://www.cbs.nl/nl-nl/artikelen/nieuws/2008/16/bijna-evenveel-hoogopgeleide-als-laagopgeleide-nederlanders/opleidingsniveau2019>].
28. Hibbard JH, Greene J, Shi Y, et al. Taking the long view: how well do patient activation scores predict outcomes four years later? *Med Care Res Rev* 2015;72(3):324-37. doi: 10.1177/1077558715573871
29. Fransen MP, Leenaars KE, Rowlands G, et al. International application of health literacy measures: adaptation and validation of the newest vital sign in The Netherlands. *Patient Educ Couns* 2014;97(3):403-9. doi: 10.1016/j.pec.2014.08.017
30. Weymiller AJ, Montori VM, Jones LA, et al. Helping patients with type 2 diabetes mellitus make treatment decisions: statin choice randomized trial. *Arch Intern Med* 2007;167(10):1076-82. doi: 10.1001/archinte.167.10.1076
31. Legare F, Adekpedjou R, Stacey D, et al. Interventions for increasing the use of shared decision making by healthcare professionals. *Cochrane Database Syst Rev* 2018;7:CD006732. doi: 10.1002/14651858.CD006732.pub4



- 1  
2  
3 32. Halvorsen PA, Selmer R, Kristiansen IS. Different ways to describe the benefits of risk-reducing  
4 treatments: a randomized trial. *Ann Intern Med* 2007;146(12):848-56.  
5  
6 33. Adarkwah CC, Jegan N, Heinzl-Gutenbrunner M, et al. Time-to-event versus ten-year-absolute-  
7 risk in cardiovascular risk prevention - does it make a difference? Results from the  
8 Optimizing-Risk-Communication (OptRisk) randomized-controlled trial. *BMC Med Inform*  
9 *Decis Mak* 2016;16(1):152. doi: 10.1186/s12911-016-0393-1  
10  
11 34. Krones T, Keller H, Sonnichsen A, et al. Absolute cardiovascular disease risk and shared decision  
12 making in primary care: a randomized controlled trial. *Ann Fam Med* 2008;6(3):218-27. doi:  
13 10.1370/afm.854  
14  
15 35. Fried TR, Tinetti ME, Towle V, et al. Effects of benefits and harms on older persons' willingness to  
16 take medication for primary cardiovascular prevention. *Arch Intern Med* 2011;171(10):923-  
17 8. doi: 10.1001/archinternmed.2011.32  
18  
19 36. Wouters H, Van Dijk L, Geers HC, et al. Understanding Statin Non-Adherence: Knowing Which  
20 Perceptions and Experiences Matter to Different Patients. *PLoS One* 2016;11(1):e0146272.  
21 doi: 10.1371/journal.pone.0146272  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

1  
2  
3 Figure Legends:  
4

5 Figure 1: Participant flow during the trial  
6

7  
8 Figure 2: DCS at 1 month and Kruskal-Wallis analysis of variance and pos-hoc Wilcoxon-  
9  
10 rank sum t-test. Boxes denote the median (25<sup>th</sup>-75<sup>th</sup> percentiles). Whiskers denote the 25<sup>th</sup>  
11  
12 percentile-1.5\*(Inter-Quartile Range) and the 75<sup>th</sup> percentile + 1.5(Inter Quartile Range).  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only

## Tables:

**Table 1:** Baseline characteristics

	Control-group	iAR-group	iLE-group
	n=101	n=101	n=101
Age	66(59-70)	66(58-71)	64(59-71)
Gender (male)	86%	82%	85%
More than one CVD location	11%	10%	10%
Current Smoker	17%	16%	9%
Years clinically manifest CVD	0(0-10)	0(0-10)	3(0-10)
Diabetes Mellitus	14%	27%	23%
LDL-cholesterol (mmol/L)	2.0(1.7-2.4)	2.0(1.6-2.4)	2.0(1.6-2.5)
LDL-cholesterol > 1.8 mmol/L	65%	67%	60%
Already on maximum statin therapy	1.3%	1.0%	1.0%
Creatinin (umol/L)	84(78-93)	83(75-96)	85(75-94)
Systolic blood pressure (mmHg)	131(121-142)	131(121-143)	129(122-142)
Number of medications per day	5(4-6)	6(4-9)	6(4-8)
Disutility score	61(9-97)	61(5-97)	61(9-97)
Adequate health literacy	83%	83%	81%

**Legend:** Data are reported as mean  $\pm$  SD, median (interquartile range) or (%). CVD locations defined as coronary artery disease, peripheral artery disease, or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy was based on the Newest Vital Sign score in the baseline questionnaire.<sup>29</sup> Disutility is months required to offset inconvenience of daily pill-taking of an idealized medication.<sup>8</sup> Number of medications excludes over the counter medications, (nasal) sprays, and topical medications. Maximum therapy was atorvastatin 80 mg.


1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60

For peer review only


**Table 2:** Patient Reported Secondary Outcomes

	Median (25 <sup>th</sup> -75 <sup>th</sup> percentile)			p-value
	Control-group	iAR-group	iLE-group	
DCS (6)	25(16-38)	22(9-29)	25(7-31)	p=0.10*
Brief-IPQ (1)	36(26-42)	34(28-44)	37(30-42)	p=0.68
Brief-IPQ (6)	34(26-43)	35(30-41)	37(29-44)	p=0.19
PAM (1)	60(51-70)	58(53-68)	63(56-75)	p=0.20
PAM (6)	64(54-77)	63(56-77)	63(56-78)	p=0.48
Perceived Statin Efficacy (1)	8(7-9)	8(7-9)	8(7-9)	p=0.92*
Perceived Statin Efficacy (6)	8(7-9)	8(7-9)	8(7-9)	p=0.98*
Understanding of therapy-effects (1)	88(75-88)	88(75-100)	88(75-100)	p=0.07*
Understanding of therapy-effects (6)	88(75-100)	88(75-100)	88(63-100)	p=0.60*
BMQ Adherence Risk Scale (1)	1(0-1)	1(0-1)	1(0-1)	p=0.60*
BMQ Adherence Risk Scale (6)	1(0-1)	1(0-1)	1(0-1)	p=0.41*
SDMQ9 (1); Reported visiting GP (n)	44(9-69); (46)	42(18-62);	58(22-76); (55)	p=0.40*
SDMQ9 (6); reported visiting GP (n)	44(24-73); (60)	48(32-63);	62(22-84); (47)	p=0.28*
RAND-36 Quality of life (6)				
Physical functioning	80(70-85)	75(60-85)	80(65-85)	p=0.11*
Role limitations due to physical health	80(70-85)	75(60-85)	80(65-85)	p=0.57*
Role limitations due to emotional problems	100(100-100)	100(100-100)	100(100-100)	p=0.80*
Energy/fatigue	75(65-80)	70(60-80)	73(55-80)	p=0.20*
Emotional well-being	84(73-92)	84(72-92)	80(72-88)	p=0.11*
Social Functioning	88(75-88)	88(63-88)	88(75-88)	p=0.49*
Pain	90(78-100)	90(68-100)	100(78-100)	p=0.93*
General health	70(55-75)	60(49-75)	65(50-74)	p=0.10*

Legend: Data are for one (1) or six (6) months. Bonferroni p-value for significance was 0.002. \* Denotes a non-parametric test was applied.



1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41



DCS at 1 month and Kruskal-Wallis analysis of variance and pos-hoc Wilcoxon-rank sum t-test. Boxes denote the median (25th–75th percentiles). Whiskers denote the 25th percentile-1.5\*(Inter-Quartile Range) and the 75th percentile + 1.5(Inter Quartile Range).

268x169mm (72 x 72 DPI)

## Supplement

### Supplement 1 (A, B, and C):

The following examples are for a 55-year-old non-smoking non-diabetic Dutch male, with a history of coronary heart disease systolic blood pressure of 140 mmHg, a total cholesterol of 6.0 mmol/L, a creatinine of 93 umol/L, and LDL-cholesterol of 3.4 mmol/L. The patient currently uses atorvastatin 40 mg. *Disclaimer: These examples are for a fictionalized, hypothetical patient and not based on any actual individual.*

#### Supplement 1A: Anonymous example of standard-care.

Cholesterol:

Prevention program findings

The concentration of cholesterol in your blood is elevated. An elevated cholesterol level can increase the atherosclerotic process, or the accumulation of cholesterol and other deposits in the walls of your blood vessels.

Advice from the vascular team:

You are already being treated with a cholesterol lowering medication. Yet, your cholesterol level is still elevated. We therefore recommend adjusting the dose of your cholesterol lowering medication or switching to different cholesterol lowering medication. Talk to your doctor about considering this switch.

You can find more information about cholesterol and other risk factors on the internet: [www.cholesterol.nl](http://www.cholesterol.nl), [www.hartstichting.nl](http://www.hartstichting.nl), [www.voedingscentrum.nl](http://www.voedingscentrum.nl) and [www.vaatcentrum.nl](http://www.vaatcentrum.nl).



**Supplement 1B: Example of a ‘personal health profile’ for a hypothetical patient in the individualized absolute risk arm. Disclaimer: This is a fictionalized, hypothetical patient**

1  
2  
3  
4  
5  
6  
7  
8  
9  
10  
11  
12  
13  
14  
15  
16  
17  
18  
19  
20  
21  
22  
23  
24  
25  
26  
27  
28  
29  
30  
31  
32  
33  
34  
35  
36  
37  
38  
39  
40  
41  
42  
43  
44  
45  
46  
47  
48  
49  
50  
51  
52  
53  
54  
55  
56  
57  
58  
59  
60



**My Personal Health Profile**

Part of the SMART-INFORM study

In this folder you will find your personal health profile, which we have made as part of your participation in the SMART-INFORM study. Elements of your medical status were used to complete the profile.

**VIDEOS MADE FOR YOU**

In this envelope, you will find six short videos designed to give you a bit of background information about this health profile and cardiovascular disease in general. The six videos are:

1. What is cardiovascular disease?
2. What is cholesterol?
3. What does a statin do?
4. Do statins have side-effects?
5. How do I read my personal health profile
6. What now?

The videos have been loaded onto the USB-card you are receiving with this Health Profile. You can watch the videos by plugging the USB card into a computer.

**PERSONAL HEALTH PROFILE**

- Mr. J. Smith  
73 years old
- Type of cardiovascular disease  
Heart
- You are a non-smoker
- Creatinine-level (Kidney function)  
100 umol/L
- Blood pressure  
140 / 90 mmHg
- Prescribed statin  
Simvastatin 40 mg
- Total cholesterol  
4.7 mmol/L
- You do not have diabetes
- You do not report having atrial fibrillation (a type of abnormal heart rhythm)
- You do not report having heart-failure

In order to calculate how statin medication effects your prognosis, we used the aspects of your profile listed above. We have based these aspects on the medical records on-file at the hospital.

2

**10-YEAR RISK**

A 10-year risk estimates the chance that you will suffer a heart attack, stroke, or sudden death with the next 10 years. We have estimated your 10-year risk in three different situations from which you can choose.

**THREE SITUATIONS FROM WHICH TO CHOOSE**

You can choose from the following three situations:

1. Continue with your current statin and dose, this is your current prognosis.
2. Stop taking your statin.
3. Increase your statin effectiveness by taking the highest dose of the strongest statin (atorvastatin 80mg).

**1. CONTINUE**



If you continue on your current statin and dose, your 10-year risk will be **21 %**

**2. STOP**



If you stop taking your statin, your 10-year risk will be **29 %**

**3. INCREASE**



If you increase your statin dose, your 10-year risk will be **18 %**

3

**QUESTIONS?**

If you have any questions about the SMART-INFORM study you can contact the investigators. They can be reached on weekdays on 000 00 000 00.

**WE WILL CONTACT YOU**

Within a few weeks, a researcher will be in contact with you to answer any additional questions or provide additional explanation regarding the personal health profile.



4

## Supplement 1C: Example of a 'personal health profile' for a hypothetical patient in the individualized life-expectancy arm. *Disclaimer: This is a fictionalized, hypothetical patient*



### My Personal Health Profile

Part of the SMART-INFORM study

In this folder you will find your personal health profile, which we have made as part of your participation in the SMART-INFORM study. Elements of your medical status were used to complete the profile.

### VIDEOS MADE FOR YOU

In this envelope, you will find six short videos designed to give you a bit of background information about this health profile and cardiovascular disease in general. The six videos are:

1. What is cardiovascular disease?
2. What is cholesterol?
3. What does a statin do?
4. Do statins have side-effects?
5. How do I read my personal health profile
6. What now?

The videos have been loaded onto the USB-card you are receiving with this Health Profile. You can watch the videos by plugging the USB card into a computer.

### PERSONAL HEALTH PROFILE

Mr. J. Smith 73 years old	Type of cardiovascular disease Heart
You are a non-smoker	Creatinine-level (Kidney function) 100 umol/L
Blood pressure 140 / 90 mmHg	Prescribed statin Simvastatin 40 mg
Total cholesterol 4.7 mmol/L	You do not have diabetes
You do not report having atrial fibrillation (a type of abnormal heart rhythm)	You do not report having heart-failure

In order to calculate how statin medication affects your prognosis, we used the aspects of your profile listed above. We have based these aspects on the medical records on-file at the hospital.

2

### DISEASE-FREE LIFE EXPECTANCY

The disease-free life-expectancy indicates how long you can expect to live without having a heart attack, stroke, or sudden death. We have estimated your disease-free life expectancy in three different situations from which you can choose.

### THREE SITUATIONS FROM WHICH TO CHOOSE

You can choose from the following three situations:

1. Continue with your current statin and dose, this is your current prognosis.
2. Stop taking your statin.
3. Increase your statin effectiveness by taking the highest dose of the strongest statin (atorvastatin 80mg).

#### 1. CONTINUE

If you continue with your current statin and dose, your disease-free life-expectancy is **76 years**

#### 2. STOP

If you stop taking your statin, your disease-free life-expectancy will be **22 months shorter**

#### 3. INCREASE

If you increase your statin dose, your disease-free life-expectancy will be **9 months longer**

3

### QUESTIONS?

If you have any questions about the SMART-INFORM study you can contact the investigators. They can be reached on weekdays on 000 00 000 00.

### WE WILL CONTACT YOU

Within a few weeks, a researcher will be in contact with you to answer any additional questions or provide additional explanation regarding the personal health profile.



4

### Supplement 2: Telephone consultation


Short motivational telephone consultation following a structured interview asking the following questions:

- Did you receive the information?
- Have you been able to watch the videos?
- Did you understand all the information?
- Which questions did you have after studying the information?
- Did you already decide which statin treatment option you prefer?
- If yes, did you discuss this with your physician?

### Supplement 3: Visual analogue scale

#### Estimation of therapy-effects

How great do you think the beneficial effects of your cholesterol lowering statin therapy are for you? Circle one number on the scale Below. A zero "0" means you believe that this medication is NOT effective for you and a ten "10" means you believe that is medication is VERY effective for you.



**Supplement 4: Patient questionnaire to assess statin knowledge**

---

What do you know about medication?

---

Below are a number of statements with answer choices. Please circle the answer choice which you believe is correct. If you do not know the correct answer, you can mark 'I don't know'

**Where in the body can you get cardiovascular disease?**

- heart                       legs                       both                       I don't know

Possible side-effects of statins is/are

- muscle pain                       breathing problems                       neither one                       I don't know

**A high cholesterol gives a greater risk of**

- stomach bleeds                       muscle or joint pain                       stroke/heart-attack                       I don't know

**By using statins, I reduce my risk of**

- stomach bleeds                       pneumonias                       heart-attacks                       I don't know

Due to the use of statins, the cholesterol levels in my blood will

- increase                       decrease                       stay the same                       I don't know

**Through the use I statins, I reduce**

- the fatty plaques in my arteries                       my blood pressure                       both                       I don't know

**How long are people usually advised to use statins?**

- for life                       0-1 years                       1-10 years                       I don't know

**How does cholesterol get into to blood?**

- My body produces cholesterol                       I get it from my food                       Both answers are correct                       I don't know

**Supplement 5: Secondary outcomes score ranges**

Scores on the IPQ range from 0 (non-threatening) to 80 (very threatening).<sup>21</sup> Patient Activation Measure (PAM-13) scores range from 0 (low activation) to 100 (high activation).<sup>22</sup> Perceived statin efficacy ranged from 0 (statins perceived as ineffective) to 10 (high level of statin effectiveness). The 9-item shared decision-making questionnaire ranged from 0 (poor shared decision-making) to 100 (optimal shared decision-making).<sup>29</sup> BMQ Adherence Risk Scale ranged from 0 (no-self-reported non-adherence) to 4 (self-reported non-adherence). Understanding of statin-therapy ranges from 0 (no answer correct) to 100 (all answers correct). RAND Medical Outcomes Study Short Form Survey (SF-36) questionnaire ranges from 0 (low quality of life) to 100 (high quality of life).<sup>20</sup>

**Supplement 6: General practitioner questionnaire**

	Definitely not (1)	Probably not (2)	Uncertain (3)	Probably yes (4)	Definitely yes (5)
1. How convinced are you that a statin is worthwhile for this patient?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
2. Do you think the patient could benefit from a greater statin dose?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
3. Would you consider statin discontinuation in this patient if the guidelines allowed?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
The following three questions are only applicable if the patient was part of an intervention arm.					
4. How probable is it that you would use this information to aid in doctor-patient communication?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
5. Do you think the consultation would be more efficient if you had this information beforehand?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>
6. Do you think this information would encourage therapy-adherence?	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>	<input type="checkbox"/>

**Legend:** Questions 1-3 were asked of every GP. Questions 4-6 were additionally asked for physicians with patients randomized to the individualized absolute risk or the individualized life-expectancy groups.

**Supplement table 1:** Baseline characteristics per missing and non-missing for primary outcome

	Control		iPOL		iARR	
	Non-missing	Missing	Non-missing	Missing	Non-missing	Missing
Population	n=90	n=11	N=87	N=14	N=83	N = 18
Age	64 (59 - 72)	62 (60 - 67)	66 (59-71)	68 (59-73)	66 (59-72)	63 (59 – 68)
Gender (male)	77 (85%)	9 (82%)	72 ( 83%)	11 (79%)	71 (86%)	16 (89%)
One CVD location	79 (88%)	10 (91%)	77 (89%)	14 (100%)	75 (90%)	15 (83%)
Current smokers	13 (16%)	4 (22%)	9 (10%)	1 (9%)	9 (10%)	1 (9%)
Years clinically manifest CVD	5 (0 - 11)	0 (0 - 12)	5 (0-10)	0 (0-2)	0 (0-10)	6 (0-12)
Diabetes Mellitus	19 (21%)	4 (36%)	24 (28%)	3 (21%)	13 (16%)	1 (6%)
LDL-c (mmol/L)	2.0 (1.6 - 2.5)	1.8 (1.6 - 2.4)	2.1 (1.7 - 2.4)	1.7 (1.6 - 2.1)	2.0 (1.6 - 2.4)	2.0 (1.7 - 2.3)
LDL-c >1.8mmol/L	56 (62%)	5 (50%)	62 (71%)	6 (43%)	55 (66%)	11 (61%)
Creatinine (umol/L)	85 (75 - 92)	85 (74 - 97)	82 (74 – 96)	91 (80 – 106)	83 (78 – 95)	85 (80 – 90)
Systolic blood pressure (mmHg)	129 (122 - 142)	132 (116 - 150)	132 (121- 145)	129 (120- 132)	130 (121 - 140)	140 (124- 148)
Number of medications per day	5 (4 - 7)	7 (5 - 10)	6 (4-9)	7 (6-8)	5 (4 - 7)	5 (4 - 6)
Months required to offset disutility of daily pill-taking	42 (9 - 97)	97 (35 - 97)	61 (3 – 97)	97 (70 – 97)	61 (9-97)	12 (9-61)
High likelihood limited literacy	6 (7%)	2 (18%)	6 (7%)	2 (14%)	5 (4%)	4 (22%)
Possibility of limited literacy	9 (10%)	2 (18%)	7 (8%)	2 (14%)	7 (9%)	1 (56%)
Adequate literacy	75 (83%)	7 (63%)	74 (85%)	10 (71%)	70 (85%)	13 (72%)

**Legend:** Data are reported as median (interquartile range) or n (%). CVD locations defined as coronary artery disease, peripheral artery disease, or abdominal aortic aneurysm in addition to cerebrovascular disease. Health literacy based on the Newest Vital Sign baseline questionnaire.<sup>29</sup> Number of medications excludes over the counter medications, (nasal) sprays, and topical medications.

**Supplemental table 2:** Physician reported secondary outcomes

	Median (IQR)			Two-sided p-value
	Control-group	iAR-group	iLE-group	
<b>Post-interventional LDL-c</b>				
LDL-c values determined	n=55	n=43	n=43	
No LDL-c values determined	n=27	n=42	n=42	
Unknown**	n=19	n=21	n=16	
Post-interventional LDL-c at 6 months (mmol/L)	1.9 (1.6 - 2.3)	1.9 (1.4 - 2.3)	1.9 (1.5 - 2.4)	p=0.60
<b>Physician opinion of intervention</b>				
Approached	n=93	n=88	n=87	
Participated	n=51	n=48	n=42	
Convinced that a statin is worthwhile for the patient*	5 (4-5)	5 (5-5)	5 (5-5)	p=0.50
Believes patient could use a higher dose*	3 (2-4)	3 (2-4)	3 (2-4)	† p=0.11
Would consider statin discontinuation if guidelines allowed*	2 (1-3)	2 (1-4)	2 (1-4)	† p=0.84
How probable to use information†*	N/A	4 (4-5)	4 (3-5)	† p=0.84
Believes that consultation would be more efficient†*	N/A	4 (3-5)	4 (3-5)	p=0.4
Believes that information would encourage therapy adherence†*	N/A	4 (3-5)	4 (3-4)	p=0.50

**Legend:** Data are reported as median (interquartile range) or n (%). †Only applicable for the intervention groups LDL-c=low-density lipoprotein cholesterol. Precise questions and answer choices are shown in supplement 6 "General Practitioner Questionnaire."

\*Median numbers of five-point scale where 1 = definitely not, 2= probably not, 3= uncertain, 4= probably yes, 5 = definitely yes.

\*\* No link with dossier from general practitioner possible after six months. † Denotes a non-parametric test was applied.

**Supplemental table 3: Median DCS score per subgroup strata**

	Control –group		iAR –group		iLE –group	
<b>Gender</b> (F=7.02, p-value for interaction=0.32)						
Men	29.7 (19.5 - 42.2)	n=71	23.4 (11.7 - 29.7)	n=72	25.0 (10.9 - 32.8)	n=77
Women	25.8 (21.0 - 47.7)	n=12	14.1 (10.2 - 25)	n=15	26.6 (9.4– 29.7)	n=13
<b>Age</b> (F=0.17, p-value for interaction=0.90)						
>65	19.0 (20.3 - 42.2)	n=45	18.8 (9.0 - 28.6)	n=44	25.0 (8.6 - 31.3)	n=42
≤65	30.0 (19.5 - 42.6)	n=38	23.5 (13.3 - 30.7)	n=43	25.0 (12.9 - 31.6)	n=48
<b>Patient activation measure</b> (F=1.4, p-value for interaction=0.40)						
Low	26.7 (14.8 - 39.1)	n=21	21.9 (3.1 - 25.0)	n=13	26.6 (24.2 - 49.2)	n=15
High	26.7 (25.2 - 42.2)	n=43	23.4 (12.5 - 30.7)	n=43	22.4 (4.7 - 29.7)	n=49
<b>Years since first CVD-event</b> (F=1.4, p-value for interaction=0.24)						
>1 year	29.7 (20.3 - 45.3)	n=33	23.4 (4.7 - 29.7)	n=43	25.0 (14.9 - 33.2)	n=52
≤1 year	26.7 (19.9 - 39.8)	n=50	21.0 (14.1 - 30.0)	n=44	23.5 (5.5 - 33.2)	n=38
<b>Educational level</b> (F=2.8, p-value for interaction=0.09)						
Low	28.1 (25.0 - 37.5)	n=14	6.3 (3.1 - 18.8)	n=17	14.1 (1.6 - 25.0)	n=15
Middle	29.7 (13.3 - 46.1)	n=35	25.0 (16.4 - 30.7)	n=40	25.0 (22.3 - 30.5)	n=38
High	26.6 (20.7 - 41.0)	n=34	21.9 (17.2 - 30.9)	n=30	25.0 (7.8 - 34.4)	n=37
<b>Health literacy*</b> (F=4.0, p-value for interaction=0.02)						
High likelihood limited literacy	50.0 (29.7 - 53.1)	n=5	7.8 (3.1 - 13.7)	n=6	28.1 (25.0 - 31.3)	n=6
Possibility limited literacy	31.2 (25.0 - 41.4)	n=7	29.7 (18.7 - 30.5)	n=7	25.0 (0.0 - 42.1)	n=9
Adequate literacy	26.6 (18.8 - 41.8)	n=70	22.7 (12.9 - 29.7)	n=74	23.4 (8.6 - 29.7)	n=75
<b>Disutility</b> (F=0.6, p-value for interaction=0.54)						
Low (<9 months)	26.6 (14.1 - 45.3)	n=23	18.8 (3.1 - 25.0)	n=25	22.7 (9.0 - 25.4)	n=24
Middle (9-97 months)	32.0 (23.4 - 44.5)	n=18	23.4 (20.7 - 28.5)	n=14	27.3 (14.8 - 41.8)	n=26
High (>97 months)	32.0 (25.0 - 43.0)	n=24	17.2 (3.1 - 29.7)	n=31	23.4 (0.39 - 35.0)	n=22


**Legend:** Data are reported as median (25<sup>th</sup> – 75<sup>th</sup> percentile). \*Further analyses for health-literacy are shown in supplemental figure 2. Health literacy based on the Newest Vital Sign.<sup>29</sup>




Supplemental table 4: Sensitivity analyses: Patient Reported Secondary Outcomes corrected for baseline characteristics.

	ANCOVA
	p-value
DCS (1)	p=0.49
DCS (6)	p=0.50
Brief-IPQ (1)	p=0.21
Brief-IPQ (6)	p=0.63
PAM (1)	p=0.39
PAM (6)	p=0.29
Perceived Statin Efficacy (1)	p=0.67
Perceived Statin Efficacy (6)	p=0.44
Understanding of therapy-effects (1)	p=0.16
Understanding of therapy-effects (6)	p=0.60
BMQ Adherence Risk Scale (1)	p=0.382
BMQ Adherence Risk Scale (6)	p=0.32
SDMQ9 (1); Reported visiting GP (n)	p=0.21
SDMQ9 (6); reported visiting GP (n)	p=0.35
RAND-36 Quality of life (6)	
Physical functioning	p=0.12
Role limitations due to physical health	p=0.48
Role limitations due to emotional problems	p=0.69
Energy/fatigue	p=0.86
Emotional well-being	p=0.25
Social Functioning	P = 0.71
Pain	p = 0.53
General health	P = 0.86

Sensitivity analyses for all outcomes at one (1) and six (6) months post intervention corrected for baseline characteristics: gender, age, smoking status, diabetes status, LDL-cholesterol (mmol.L), creatinine (umol/L), disutility score, NVS health literacy, and number of medications used per day



**Supplemental Figure 1:** Therapy-benefit from statin intensification to atorvastatin 80mg for a) iAR arm and b) iLE arm. Loss of benefit from statin discontinuation in c) iAR arm and d) iLE arm. In the iAR group, the median baseline 10-year absolute CVD risk was 37.6% (28.1-49.0). The estimated absolute 10-year risk change was -2.4% (-1.2 to -3.9) after intensification and 10.2% (7.7- 13.5) after discontinuation. In the iLE group, the median CVD-free life-expectancy was 75.4 years (73.0-82.7). The median change in CVD-free life-years was 0.5 years (0.3 – 0.8) after intensification and -2.0 years (- 1.3 - - 2.8) after discontinuation.



**Supplemental figure 2:** Subgroup analysis. Box-and-whisker plot depict the decisional conflict score at one month stratified by baseline health literacy. The colored boxes denote the median (25th – 75th percentiles). Whiskers denote the 25th percentile-1.5\*(Inter-Quartile Range) and the 75th percentile + 1.5(Inter Quartile Range) in whiskers.



## CONSORT 2010 checklist of information to include when reporting a randomised trial\*

Section/Topic	Item No	Checklist item	Reported on page No
<b>Title and abstract</b>			
	1a	Identification as a randomised trial in the title	2
	1b	Structured summary of trial design, methods, results, and conclusions (for specific guidance see CONSORT for abstracts)	2/3
<b>Introduction</b>			
Background and objectives	2a	Scientific background and explanation of rationale	5
	2b	Specific objectives or hypotheses	5
<b>Methods</b>			
Trial design	3a	Description of trial design (such as parallel, factorial) including allocation ratio	6/7
	3b	Important changes to methods after trial commencement (such as eligibility criteria), with reasons	NA
Participants	4a	Eligibility criteria for participants	6
	4b	Settings and locations where the data were collected	6
Interventions	5	The interventions for each group with sufficient details to allow replication, including how and when they were actually administered	7/8
Outcomes	6a	Completely defined pre-specified primary and secondary outcome measures, including how and when they were assessed	9-10 manuscript and in supplemental material
	6b	Any changes to trial outcomes after the trial commenced, with reasons	N/A
Sample size	7a	How sample size was determined	10/11
	7b	When applicable, explanation of any interim analyses and stopping guidelines	NA
<b>Randomisation:</b>			
Sequence generation	8a	Method used to generate the random allocation sequence	6
	8b	Type of randomisation; details of any restriction (such as blocking and block size)	6
Allocation concealment mechanism	9	Mechanism used to implement the random allocation sequence (such as sequentially numbered containers), describing any steps taken to conceal the sequence until interventions were assigned	6

1	Implementation	10	Who generated the random allocation sequence, who enrolled participants, and who assigned participants to interventions	6
2				
3	Blinding	11a	If done, who was blinded after assignment to interventions (for example, participants, care providers, those assessing outcomes) and how	6, more details in 10
4		11b	If relevant, description of the similarity of interventions	7/8
5	Statistical methods	12a	Statistical methods used to compare groups for primary and secondary outcomes	11
6		12b	Methods for additional analyses, such as subgroup analyses and adjusted analyses	11
7				
8				
9				
10	<b>Results</b>			
11	Participant flow (a diagram is strongly recommended)	13a	For each group, the numbers of participants who were randomly assigned, received intended treatment, and were analysed for the primary outcome	12 and figure 1
12		13b	For each group, losses and exclusions after randomisation, together with reasons	Page 12, figures 1 and supplemental table 1
13				
14				
15				
16				
17				
18	Recruitment	14a	Dates defining the periods of recruitment and follow-up	12
19		14b	Why the trial ended or was stopped	12
20				
21	Baseline data	15	A table showing baseline demographic and clinical characteristics for each group	Table 1, supplemental table 1
22				
23				
24				
25	Numbers analysed	16	For each group, number of participants (denominator) included in each analysis and whether the analysis was by original assigned groups	Page 12. Figure 1.
26				
27	Outcomes and estimation	17a	For each primary and secondary outcome, results for each group, and the estimated effect size and its precision (such as 95% confidence interval)	Figure 2, table 2
28		17b	For binary outcomes, presentation of both absolute and relative effect sizes is recommended	NA
29				
30	Ancillary analyses	18	Results of any other analyses performed, including subgroup analyses and adjusted analyses, distinguishing pre-specified from exploratory	Pg 14, supplemental table 4
31				
32				
33				
34				
35	Harms	19	All important harms or unintended effects in each group (for specific guidance see CONSORT for harms)	NA
36				
37	<b>Discussion</b>			
38	Limitations	20	Trial limitations, addressing sources of potential bias, imprecision, and, if relevant, multiplicity of analyses	Pg 16
39				
40	Generalisability	21	Generalisability (external validity, applicability) of the trial findings	Pg 16
41	Interpretation	22	Interpretation consistent with results, balancing benefits and harms, and considering other relevant evidence	Pg 14-17
42				

1	<b>Other information</b>			
2	Registration	23	Registration number and name of trial registry	Pg 6
3	Protocol	24	Where the full trial protocol can be accessed, if available	Pg 18
4	Funding	25	Sources of funding and other support (such as supply of drugs), role of funders	Pg 18

7 \*We strongly recommend reading this statement in conjunction with the CONSORT 2010 Explanation and Elaboration for important clarifications on all the items. If relevant, we also  
8 recommend reading CONSORT extensions for cluster randomised trials, non-inferiority and equivalence trials, non-pharmacological treatments, herbal interventions, and pragmatic trials.  
9 Additional extensions are forthcoming: for those and for up to date references relevant to this checklist, see [www.consort-statement.org](http://www.consort-statement.org).

For peer review only